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OUTLINE OF THE THESIS 
In Chapter 1, the rational for this study will be presented focusing on explain the potential 
impact of Single Nucleotide Polymorphisms (SNPs), in genes involved in DNA regulation, 
on Gastric Cancer susceptibility.      
In Chapter 2, it will be presented a systematic review and meta-analysis regarding the 
association of SNPs of DNA methyltransferases (DNMTs) with gastric cancer. This 
chapter is presented as the following article: 
Neves M, Ribeiro J, Medeiros R, Sousa H. Genetic polymorphism in DNMTs and 
gastric cancer: a systematic review and meta-analysis. (prepared to submit to 
Porto Biomedical Journal)  
In Chapter 3, it will be characterized the association of DNMT2 and DNMT3A SNPs with 
the development of gastric lesions and gastric adenocarcinoma in a population from the 
northern region of Portugal. This chapter is presented as the following article: 
Neves M, Ribeiro J, Dinis-Ribeiro M, Medeiros R, Sousa H. Single Nucleotide 
polymorphisms in DNA methyltransferases and gastric cancer. (prepared to 
submit to Acta Medica) 
In Chapter 4, it will be shown the association of SNPs in SLC19A1 and MTHFR genes 
with the susceptibility to GC. This chapter is presented as the following article: 
Neves M, Francisco M, Ribeiro J, Lima A, Dinis-Ribeiro M, Medeiros R, Sousa H. 
SLC19A1 G80A and MTHFR C677T as risk factors for gastric cancer 
development. (prepared to submit to Tumor Biology)  
In Chapter 5, it will be summarized the importance of the results obtained in this thesis. 
Up to our knowledge, this is the first study to evaluate the association of SNPs in 
SLC19A1, MTHFR and DNMTs with GC, in the Portuguese population. 
Finally, in Chapter 6, it will be presented the references of the thesis.  
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Gastric cancer (GC) constitutes a serious public health problem, representing the fifth 
most common diagnosed cancer with approximately 3 000 new diagnoses and 2 200 
deaths per year, in Portugal. GC carcinogenesis is associated with several risk factors, 
such as, environmental factors (Helicobacter pylori, diet, obesity, smoking), epigenetic 
alterations and genetic susceptibility. Regarding epigenetic alterations, studies have 
shown that aberrant DNA methylation have a role in GC carcinogenesis. Therefore, 
genetic alterations in genes responsible for DNA methylation (DNA methyltransferases) 
may have an impact on GC development. Other risk factor that has been associated with 
GC is low folate intake. Folates are important for DNA regulation, thereby alterations in 
genes important for folate metabolism might affect individual’s susceptibility for GC. 
Genetic polymorphisms, such as single nucleotide polymorphisms (SNPs), have been 
studied and associated with altered protein functions and, consequently, with the 
development of cancer. Several studies suggest that SNPs in genes important for DNA 
methylation might have an influence on the susceptibility for GC. 
We developed a study to analyze the role of some SNPs in GC development. The study 
was performed with a population from the northern region of Portugal with gastric lesions 
(n=43), GC (n=137) and a cancer-free control group (n=250). SNPs were selected based 
on literature and genetic characterization was performed with different methodologies. 
Firstly, we performed a systematic review and meta-analysis to evaluate which SNPs in 
DNA methyltransferases (DNMTs) may be associated to GC, according to literature. The 
results showed that DNMT2 rs11254413, DNMT3A rs7560488, DNMT3A rs36012910 
and, specially, DNMT1 rs16999593 seem to be good candidates to study the role of 
SNPs in DNMTs in GC development. Then, we aimed to characterize DNMT2 
rs11254413 and DNMT3A rs7560488 genotypes and their association with GC, in our 
population. Our results showed that there is no association between both SNPs and GC 
development. Finally, another aim of our study was to analyze the association between 
SLC19A1 G80A and MTHFR C677T with GC development. Regarding the results 
obtained for SLC19A1 G80A genotypes, we observed a protective effect for gastric 
lesion (OR=0.373; 95%CI=0.189-0.736; p=0.006), but not with GC. On the other hand, 
MTHFR C677T was associated with an increased risk for GC development (OR=2.046; 
CI 95%=1.323-3.165; p=0.001), but it was not associated with gastric lesions. 
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This study revealed that DNMT2 rs11254413 and DNMT3A rs7560488 polymorphisms 
are not associated with GC in our population, nevertheless SLC19A1 G80A may have a 
protective role in gastric lesions development and MTHFR C677T may be associated 
with an increased risk for GC development.  
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O cancro gástrico (CG) constitui um grave problema de saúde pública, representando o 
5º cancro mais diagnosticado com cerca de 3 000 novos diagnósticos e 2 200 mortes 
por ano, em Portugal. A carcinogénese do CG está associada a vários fatores de risco, 
tais como, fatores ambientais (Helicobacter pylori, dieta, obesidade, tabaco), alterações 
epigenéticas e suscetibilidade genética. Em relação às alterações epigenéticas, estudos 
têm mostrado que a metilação anormal do DNA tem um papel na carcinogénese do CG. 
Portanto, alterações genéticas em genes responsáveis pela metilação do DNA (DNA 
metiltransferases) podem ter um impacto no desenvolvimento do CG. Outro fator de 
risco que tem sido associado ao CG é a baixa ingestão de folatos. Os folatos são 
importantes para a regulação do DNA, pelo que alterações nos genes importantes para 
o metabolismo dos folatos podem afetar a suscetibilidade individual para o CG. Os 
polimorfismos genéticos, tais como single nucleotide polymorphisms (SNPs), têm sido 
estudados e associados a alterações nas funções das proteínas e, consequentemente, 
com o desenvolvimento de cancro. Muitos estudos sugerem que SNPs nos genes 
responsáveis pela metilação podem ter influência na suscetibilidade para o CG. 
Nós desenvolvemos um estudo para analisar o papel de alguns SNPs no 
desenvolvimento de CG. O estudo foi realizado com uma população da região Norte de 
Portugal com lesões gástricas (n=43), CG (n=137) e um grupo sem cancro (n=250). Os 
SNPs foram selecionados com base na literatura e a caracterização genética foi feita 
através de diferentes metodologias. Primeiramente, nós realizamos uma revisão 
sistemática e uma meta-análise para avaliar que SNPs em DNA metiltransferases 
(DNMTs) podem ser associados ao CG, de acordo com a literatura. Os resultados 
mostraram que os DNMT2 rs11254413, DNMT3A rs7560488, DNMT3A rs36012910 e, 
especialmente, o DNMT1 rs16999593 parecem ser bons candidatos para estudar o 
papel de SNPs em DNMTs no desenvolvimento de CG. De seguida, o nosso objetivo foi 
caracterizar os genótipos para DNMT2 rs11254413 e DNMT3A rs7560488 na nossa 
população. Os nossos resultados mostraram que não existe associação entre os dois 
SNPs e o desenvolvimento de CG. Por fim, outro objetivo do nosso estudo era analisar 
a associação entre SLC19A1 G80A e MTHFR C677T com o desenvolvimento de CG. 
De acordo com os resultados obtidos para os genótipos do SLC19A1 G80A, 
observámos um efeito protetor para a lesões gástricas (OR = 0.373; 95%CI = 0.189-
0.736; p = 0.006), mas não para o CG. Por outro lado, MTHFR C677T foi associado a 
um risco aumentado de desenvolvimento de CG (OR = 2.046; CI 95% = 1.323-3.165; p 
= 0.001), mas não associado a lesões gástricas.   
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Este estudo revelou que os polimorfismos DNMT2 rs11254413 e DNMT3A rs7560488 
não estão associados com CG na nossa população, porém o SLC19A1 G80A pode ter 
um papel protetor no desenvolvimento de lesões gástricas e o MTHFR C677T pode 
estar associado a um risco aumentado de desenvolvimento de CG. 
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I. CANCER 
Cancer could be defined as a disease where cells, with “damaged” DNA, grow without 
control and gain the potential to invade other tissues and spread to other parts of the 
body. The emergence of conditions for the development of cancer is dependent on many 
factors, such as genetic, epigenetic and environmental factors, which shows the 
complexity of this disease (1). 
According to the International Agency for Research on Cancer (IARC), cancer is one of 
the leading causes of mortality worldwide, with 8.2 million deaths in 2012 (13% of all 
deaths) (2,3). In the same year, 14 million new cases of cancer were reported and it is 
expected a 70% increase of new cases of cancer in the next 20 years (3). The top 5 
cancers worldwide, and in Portugal, are Breast, Prostate, Lung, Colorectal and Stomach, 
being breast cancer the more incident and lung cancer the one with higher mortality – 
figure 1. 
 
Figure 1. Incidence and mortality of top 5 cancer sites (both sexes) in 2012. (Adapted from 
GLOBOCAN 2012 (4)) 
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II. GASTRIC CANCER 
 
i. Epidemiology 
Gastric Cancer (GC) is the third leading cause of death by cancer, worldwide (4). It 
represents 6.8% of all incident cancer cases and 8.8% of all cancer deaths. The highest 
mortality rates are in eastern Asia (China is the country with higher mortality rates) and 
the lowers in north America. Central and eastern Europe and central and south America 
have also high mortality rates (4). In Portugal, GC represents 9.5% of all cancer deaths 
(2265 deaths) and 6.1% of all incident cases (3018 new cases) (4).  
The most frequent histological types of GC are adenocarcinomas and, according to 
Lauren classification, are divided in two sub-types: diffuse (poorly differentiated) and 
intestinal (well/moderately differentiated). Additionally, tumors that exhibit both intestinal 
and diffuse characteristics, and undifferentiated tumors are classified as indeterminate 
(5). The most sensitive and specific diagnostic test for GC is endoscopic screening, 
nevertheless the majority of GC patients are diagnosed at an advanced stage because 
of the lack of early symptoms (6). GC initiation and progression are a result of complex 
genetic and environmental interactions. GC carcinogenesis differs according to the 
histological type: the intestinal type carcinogenesis is a sequential step process, 
characterized by a start with a premalignant gastric change, such as atrophic gastritis, 
followed by intestinal metaplasia, dysplasia and, finally, gastric carcinoma; and the 
diffuse type carcinogenesis is more often associated with some genetic changes and 
there is not a consistent sequence of events, such as in the intestinal type. The diffuse 
type is associated with different pathological characteristics, such as signet ring cells and 
loss of cell cohesion (6–8). 
ii. Risk factors 
Tumorigenesis of GC is a multistep process and involve multiple factors (9,10).The major 
risk factor for the development of gastric cancer (especially the intestinal type) is the 
infection by Helicobacter pylori (HP), nevertheless, GC can also be the result of specific 
genetic alterations (7). The majority of GC cases arise sporadically and only less than 
3% are hereditary cancer syndromes (8). There are several sporadic genetic changes 
that influences GC pathogenesis, such as chromosomal instability, microsatellite 
instability, epigenetic changes, somatic gene mutations or single nucleotide 
polymorphisms (SNPs) (8). 
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The incidence of gastric cancer have been reduced since the identification of HP as a 
key factor in carcinogenesis, but other factors associated to our modern lifestyle and 
aging of population are also influencing the incidence of GC worldwide (10). The risk for 
GC increases with age and incidence rates of GC are twice higher in men comparing to 
women (4). Unhealthy habits, such as heavy alcohol drinking (four or more drinks per 
day) and smoking increases risk for GC (10). Obesity and diet are two major factors 
affecting GC incidence, nowadays. Literature shows that low consumption of fruits and 
vegetables, intake of salty and smoked food and obesity are associated with higher risk 
for GC (9–14) - figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Gastric cancer risk factors. Environmental and genetic/epigenetic factors are 
associated with gastric carcinogenesis. (9–17). 
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III. DNA REGULATION AND CANCER 
 
i. Folate intake – Folates and DNA regulation 
Folates are found naturally in a wide variety of foods, specially vegetables like spinach, 
kale, brussels sprouts and broccoli. Folates are water soluble B-vitamins essential for 
intracellular transmethylation reactions including those involved in DNA methylation and 
DNA synthesis (17). The active form of folate for cells is reduced folate 5-
methyltetrahydrofolate (5-MTHF). Reduced folates are transported into the cell by 
Reduced Folate Carrier 1 (RFC1 or SLC19A1), or metabolized by Methylene 
tetrahydrofolate reductase (MTHFR) – Figure 3 (18). MTHFR has a key role by 
converting dietary folates and folic acid (artificially form of folate) to 5-MTHF (18,19). The 
5-MTHF works as a single carbon donor used to convert homocysteine in to methionine, 
by removing a methyl group from 5-MTHF, using vitamin B12 as coenzyme. Methionine 
serves as a methyl group donor through conversion to S-Adenosyl methionine (SAM), a 
key agent for DNA methylation (18,20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Folate metabolism mechanism. (Adapted from Ulrich 2003 (21))  
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Multiple studies have demonstrated that alterations in folate metabolism, such as folate 
deficiency, low levels of folate in serum or genetic factors affecting genes in folate 
metabolism are associated with cancer, including GC (22–25). Alterations in RFC1 
activity affects the amount of reduced folates, leading to a lower concentration in the 
cells (23). MTHFR alterations and consequent reduced enzymatic activity leads to higher 
levels of homocysteine and the cycle homocysteine – methionine – SAM is disrupted, 
affecting DNA methylation and leading in to changes in the epigenetic profile (24).  
ii. Epigenetics and control of gene expression 
Epigenetics is the study of heritable and transient/reversible changes in gene expression 
that are not accompanied by a change in the DNA sequence (1). The most extensively 
studied epigenetic modification is DNA methylation, which is characterized by an addition 
of a methyl group in to the fifth carbon position of a cytosine residue in a CpG dinucleotide 
(26). Clusters of CpG dinucleotides in GC rich regions of the genome called CpG islands 
(CGI) frequently occur in the 5′-flanking promoter areas of genes, which are often 
responsible for the control of protein translation (15). Epigenetic control of gene 
expression by cytosine methylation is facilitated by the activity of DNA 
methyltransferases (DNMTs). These enzymes recognize CpGs and catalyze the 
transmethylation of cytosine by transferring methyl groups from S-adenosylmethionine 
(SAM) (26,27).  
DNA methylation was the first epigenetic mark shown to be critically involved in cancer 
development. Alterations in DNA methylation are associated with silencing of tumor 
suppressor genes and the activation of oncogenes involved in cancer (17,1). Literature 
have reported that global hypomethylation has been associated to early stages of 
carcinogenesis, causing genome-wide allelic instability (28). Paradoxically, the genomes 
of cancer cells are also characterized by promoter genes hypermethylation, typically in 
the CpG island of tumor suppressor genes and microRNA (miRNA). In fact, the 
inactivation of tumor suppressor genes through the hypermethylation of CpG islands 
within promoter methylation has been considered an important hallmark of cancer 
(17,26,29,30). 
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IV. GENETIC SUSCEPTIBILITY AND CANCER 
The human genome sequence of two individuals is only 99% similar, and 90% of the 
variations in the genome are Single Nucleotide Polymorphisms (31). SNPs are 
differences in single bases of DNA that turned out to be stable through evolution and 
where the minor allelic frequency is over 1% in the population. These variants are 
present in almost all population but some are specific from one region or population (32). 
Several studies have reported the association of SNPs with differential function of 
proteins and therefore contributing for the development of several diseases, including 
cancer (31,33,34).  
A project called Genome-Wide Association Studies (GWAS) have emerged as a 
powerful approach to identify risk alleles for common diseases (32,35). These studies 
compare two large groups of individuals, one healthy control group and one case group 
affected by a disease, including cancer (35). The enormous variety of data produced by 
GWAS and other studies regarding potential genomic markers in cancer contributes to 
population screening for genetic susceptibility to cancer. All this information may help to 
select groups of individuals who are at increased risk of cancer development and provide 
to them a preventive strategy (36).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Preventive strategy on increased risk groups may help to reduce mortality rates by 
reducing the risk of cancer development or by proving better prognosis and personalized therapy 
for the populations. (Source: National Cancer Institute, USA)    
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V. AIM OF THE DISSERTATION   
The main aim of the dissertation was to evaluate different SNPs on genes that are 
important for cellular methylation and DNA regulation and study an association with 
gastric cancer. SNPs in genes of folate metabolism and DNMTs have already been 
described in GC, nevertheless these were not studied in our population, and there are 
only few studies in eastern/Caucasian populations. By evaluating SNPs in gastric cancer 
patients and comparing with healthy controls, we expected to find associations between 
SNPs and gastric cancer risk.  
Throughout the dissertation we tried to answer specific aims through different studies: 
1) Systematic review and meta-analysis to understand witch SNPs in DNMTs may 
be associated to GC;  
2) Case-control study to understand the association of some SNPs in DNMTs with 
GC in our population; 
3) Case-control study to understand the association of SNPs in SLC19A1 and 
MTHFR with GC in our population. 
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ABSTRACT 
Epigenetics alterations, such as aberrant DNA methylation, have been associated with 
gastric carcinogenesis. Single Nucleotide Polymorphisms (SNPs) in DNA 
methyltransferases (DNMTs) may influence protein expression and therefore affect DNA 
regulation and susceptibility for Gastric Cancer (GC).  
We performed a systematic review and meta-analysis involving 11 studies and a total of 
24 SNPs in DNMTs were analysed. According to literature, only 4 SNPs, DNMT1 
rs16999593, DNMT2 rs11254413 and DNMT3A rs7560488 and DNMT3A rs36012910, 
were associated with GC. DNMT1 rs16999593 and DNMT3A rs7560488 C allele and 
DNMT3A rs36012910 G allele showed an increased risk for GC. On the other hand, 
DNMT2 rs11254413 G allele presented a protective effect for GC. Additionally, the meta-
analysis evaluated the SNPs analysed in more than one study (n=6). Results revealed 
that only DNMT1 rs16999593 had a statistically significant association with GC 
development (OR = 1.31; 95% CI = 1.08-1.60; p = 0.006 for TC+CC genotypes). 
Our study suggests that DNMT2 rs11254413, DNMT3A rs7560488, DNMT3A 
rs36012910 and, specially, rs16999593 may have an association with GC development 
and more studies with different populations are needed to verify if this SNPs are related 
with GC. 
 
KEY WORDS 
DNA methylation; DNA Methyltransferase; Single Nucleotide Polymorphism; Gastric 
Cancer  
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INTRODUCTION 
Epigenetics, and more extensively DNA methylation, has been studied in the past 
decades and associated with several diseases, including cancer. Literature shows that 
altered epigenetic control of gene expression has an important role in carcinogenesis 
(Ziogas and Roukos, 2009). DNA methylation is an important epigenetic mark in 
tumorigenesis, in which a methyl group is added to the 5’ position of cytosine residue in 
a CpG dinucleotide (CpG islands (CGI)), in the 5′-flanking promoter’s genes (Feinberg 
and Vogelstein, 1983). Aberrant methylation of promoter’s genes is an important 
hallmark of cancer cells and, in Gastric Cancer (GC), a large number of genes involved 
in carcinogenesis and clinical outcome accumulate aberrant methylation. Promoter 
methylation is an important mechanism of inactivation of tumor suppressor genes, in 
cancer cells (Feinberg and Vogelstein, 1983). 
The process of promoter methylation is catalysed by DNA Methyltransferases (DNMTs) 
which organize, regulate and maintain properly mammalian genomes (Yang et al., 2012). 
There are three types of DNMTs: DNMT1, over-expressed in human cancers including 
GC, that catalyse post-replication DNA methylation and maintain the methylation 
patterns during cell divisions (Kanai et al., 2003; Saito et al., 2001; Yang et al., 2011); 
DNMT2 which is the most conserved and has a role in both DNA and RNA methylation 
(Schaefer and Lyko, 2010); and DNMT3, which is divided in two types (DNMT3a and 
DNMT3b) that are responsible for de novo methylation during gametogenesis and 
embryogenesis, and that also seem to be over-expressed in human cancers, including 
GC (Yang et al., 2011, 2012). It is well known that gene expression can be influenced by 
single nucleotide polymorphisms (SNPs) and, in DNMTs genes, they may have 
functional consequences affecting methylation and therefore individual’s susceptibility to 
cancer development.  
Several studies have recently explored the potential association of SNPs in DNMTs with 
the susceptibility to GC, nevertheless, the observed associations of these studies are 
inconsistent and some studies are not large enough to take conclusions on the effect of 
DNMTs SNPs on GC. As a result, we have performed a meta-analysis of all eligible 
studies to understand the possible association of DNMTs SNPs with GC. 
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MATERIALS AND METHODS 
Search strategy 
The present systematic review and meta-analysis follows PRISMA guidelines for 
Systematic Review and Meta-analyses. Pubmed was searched till the end of March 2016 
and literature searching was performed by applying the following query: "dna 
modification methylases"[MeSH Terms] OR ("dna"[All Fields] AND "modification"[All 
Fields] AND "methylases"[All Fields]) OR "dna modification methylases"[All Fields] OR 
("dna"[All Fields] AND "methyltransferase"[All Fields]) OR "dna methyltransferase"[All 
Fields] OR DNMT[All Fields]) AND ("polymorphism, genetic"[MeSH Terms] OR 
("polymorphism"[All Fields] AND "genetic"[All Fields]) OR "genetic polymorphism"[All 
Fields] OR "polymorphism"[All Fields]) AND ("stomach neoplasms"[MeSH Terms] OR 
("stomach"[All Fields] AND "neoplasms"[All Fields]) OR "stomach neoplasms"[All Fields] 
OR ("gastric"[All Fields] AND "cancer"[All Fields]) OR "gastric cancer"[All Fields]. 
Inclusion and exclusion criteria 
The literature search was limited to original studies performed in humans and no 
publication year restriction was applied. Only case-control studies with histologically-
confirmed adenocarcinoma cases were included in this analysis. All DNMTs 
polymorphisms were selected for this analysis. Regarding the language of the papers, 
only studies written in English, Portuguese or Spanish were selected. Reviews, Meta-
analysis, Systematic Reviews and studies not related to gastric cancer were excluded 
for this analysis. 
Data extraction 
Two authors performed the data extraction and all disagreements were resolved with the 
opinion of a third author. For each study, the following items were collected: country, type 
of study, ethnicity, matching criteria, age (years), polymorphisms in study, genotype 
method, number of cases and controls. Data concerning genotype distribution and the 
relative risk were also extracted for all polymorphisms included in the studies. 
Statistical analysis 
The evidence of Hardy Weinberg Equilibrium (HWE) in controls was recalculated in the 
present meta-analysis through the application of the online software 
(http://www.had2know.com/academics/hardy-weinberg-equilibrium-calculator-2-
alleles.html). A p–value less than 0.05 of HWE was considered significant. 
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Meta-analysis for DNMTs SNPs was conducted by using the software Review Manager, 
version 5.3.5 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 
2014).  The calculated OR (95% CI) was performed with Mantel-Haenszel statistical 
method and Random effects analysis model. A p–value less than 0.05 was considered 
significant. 
 
RESULTS 
Literature search  
A total of 35 papers were evaluated from which only 11 matched with inclusion criteria. 
Seventeen articles were excluded due to the exclusion criteria by screening the titles and 
abstracts. After a comprehensive evaluation of the remaining 18 articles, 7 were 
excluded: 4 articles didn’t evaluate polymorphisms of DNMTs, only O6-methylguanine-
DNA methyltransferase (MGMT) (Chikan et al., 2015; Imai et al., 1995; Lin et al., 2014; 
Xiong et al., 2013); 2 articles only reported mutations on DNMTs (Kanai et al., 2003; Oh 
et al., 2014); 1 study was about allelic loss in gastric cancer (Kim et al., 2013). Finally, 
11 studies involving a total of 3049 cases and 5185 controls were included in this  
analysis – figure 1. 
Study characteristics 
Table 1 describes the principal baseline characteristics of included studies. The majority 
of the studies were performed in China (Cao et al., 2013; Fan et al., 2010; Hu et al., 
2010; Jiang et al., 2012; Wang et al., 2015; Y. Wang et al., 2005; Wu et al., 2014, 2012; 
Yang et al., 2012), one study in Iran (Khatami et al., 2009) and one in Japan (Aung et 
al., 2005). Almost all studies have selected the controls and cases using age and gender 
as matching criteria, but some studies also use match with Helicobacter Pylori infection 
and Ethnicity. The number of cases and controls varies between the studies. A total of 
24 polymorphisms were evaluated, 10 of DNMT1, 1 of DNMT2, 6 of DNMT3A and 7 of 
DNMT3B. The majority of studies were performed using Polymerase Chain Reaction – 
Restriction Fragment Length Polymorphism (PCR-RFLP) methodology, but other 
methods of genotyping were used like TaqMan assay, High Resolution Melting (HRM) 
and Matrix Assisted Laser Desorption/Ionization - Time of Flight (MALDI-TOF). 
Supplementary table 1 shows the characteristics of all polymorphisms included in the 
studies. The re-calculated HWE for controls is also shown in supplementary table 2. 
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Genotyping results     
The genotyping results of all studies are described in table 2. In this study, we have 
included data from 24 SNPs in DNMTs from the 11 studies.  
A total of 10 SNPs in DNMT1 were studied by 4 different studies (Jiang et al., 2012; 
Khatami et al., 2009; Yang et al., 2012) – table 2.1. Of these SNPs, only rs16999593, 
rs8101866 and rs2228611 have data from more than one population. Regarding the risk 
analysis, there was only one study that reported a significant risk association of one SNP 
(rs16999593) with increased risk of GC development (OR=1.45; 95%CI = 1.00–2.11;       
p = 0.05, for C allele). All other SNPs do not show statistical significance. 
Only one study evaluated SNPs in DNMT2 (Yang et al., 2012) revealing an association 
between rs112254413 SNP and protection for the development of GC, especially 
associated with A allele (OR = 0.15; 95%CI = 0.08-0.27; p <0.01) – table 2.2. 
Thirteen SNPs of DNMT3, 6 of DNMT3A and 7 of DNMT3B, were evaluated by 9 different 
studies, with 2 SNPs of each gene with more than one study (Aung et al., 2005; Cao et 
al., 2013; Fan et al., 2010; Hu et al., 2010; Wang et al., 2015, 2005, Wu et al., 2014, 
2012; Yang et al., 2012). Regarding the risk analysis, DNMT3A rs7560488 (OR = 1.65; 
95%CI = 1.19–2.29; p = 0.002, for C allele) and rs36012910 (OR = 2.36; 95%CI = 1.35–
4.14; p = 0.002, for allele G) seem to be associated with an increased risk for GC (Wu 
et al., 2014, 2012), and rs1550117 and rs13420867 show contradictory findings between 
the reported studies. In DNMT3B, only rs1569686 showed a statistically significant 
association (p<0.01) with GC, nevertheless the results are contradictory among different 
studies – tables 2.3/2.4. 
Meta-analysis results 
A meta-analysis was performed with data from all SNPs evaluated in more than one 
study - Figures 2-4.  A total of 6 SNPs were analysed: DNMT1 rs16999593, rs8101866 
and rs2228611; DNMT3A rs1550117 and rs13420827; and DNMT3B rs1569686. For the 
analysis, we have used the dominant genetic model, considering the risk genotype as 
the presence of any copy of the less frequent allele. The majority of studies showed no 
significant heterogeneity in the data reported (p>0.05). 
DNMT1: The analysis revealed that there was no heterogeneity (p>0.05) amongst the 
three SNPs tested. We found that only rs16999593 had a statistically significant 
association (p = 0.006), revealing a 31% increased risk of GC development for TC+CC 
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genotypes (OR = 1.31; 95%CI = 1.08-1.60). The rs8101866 and rs2228011 showed no 
significant differences (p>0.05) and moreover no significant impact on the risk (OR = 
1.08 and OR = 0.93, respectively) – figure 2. 
DNMT3A: Data showed that in addition to differences in the heterogeneity of rs1550117 
(p = 0.03), there is no impact on the risk association of GC development for either 
rs1550117 and rs13420827 (p = 0.20 and p = 0.19, respectively) – figure 3.  
DNMT3B: One SNP (rs2424913) was excluded from our meta-analysis because it was 
not possible to estimate the OR value. The lack of data for all genotypes in the three 
studies makes it impossible to evaluate any association (Aung et al., 2005; Hu et al., 
2010; Wang et al., 2005). The analysis revealed that the data from studies regarding 
rs1569686 are very contradictory, which result in a high heterogeneity on studies 
(p<0.001) and no risk association with GC – figure 4. 
We have also tested all data considering the Recessive Model for each SNP, and no 
significant change was observed in the reported data (data not shown).  
 
DISCUSSION 
Gastric carcinogenesis is a multistep process, where different factors are involved and 
epigenetic alterations, including DNA methylation of CGI, seem to play an important role 
in early mechanisms of carcinogenesis (Yang et al., 2011). The process of CpG 
methylation is catalysed by DNMTs and modified DNA methylation has direct effect on 
the regulation of gene expression, thus altered activity of DNMTs can affect DNA 
methylation. Literature reveals that DNMTs are frequently overexpressed in GC (Lin et 
al., 2014). Considering the significant impact of genetic susceptibility based on the 
genetic sequences of individuals, functional SNPs may affect DNMTs expression, and 
therefore, it is important to study SNPs in DNMTs and understand the effect that 
functional SNPs can have on their activity.  
Recently, several studies have been performed to evaluate the impact of DNMTs 
polymorphisms in GC susceptibility (Aung et al., 2005; Cao et al., 2013; Fan et al., 2010; 
Hu et al., 2010; Jiang et al., 2012; Khatami et al., 2009; Wang et al., 2015, 2005, Wu et 
al., 2014, 2012; Yang et al., 2012). Hence, this systematic review intends to resume the 
data published regarding the association of SNPs in DNMTs with GC. By searching 
literature, we have found 11 studies matching our inclusion criteria. One of the first 
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findings was that the majority of included studies were performed in Asiatic populations, 
where GC is extremely common (Karimi et al., 2014). This constitutes a major limitation 
for this systematic review since that is not possible to extrapolate the conclusions to 
others populations.  
There are very few studies considering DNMTs SNPs and GC susceptibility and very few 
data on different SNPs. A total of 24 SNPs were found in this systematic review, 10 in 
DNMT1, 1 in DNMT2 and 13 in DNMT3. Possible limitations of some of the included 
studies are not only population bias but also the different genotyping methods. The 
genotyping methods used were different and with different specificity: PCR-RFLP 
method has some limitations to genotype correctly the three genotypes, specially 
heterozygote genotypes (Davis et al., 2007); while TaqMan real-time PCR assays are 
more accurate and have less limitations and are a better candidate for SNP genotyping 
(Shen et al., 2009). Furthermore, the number of cases and controls included are 
extremely different among studies and therefore more studies with bigger populations 
and more precise genotyping methods are still required. 
The literature report that DNMT1 rs16999593, DNMT2 rs11254413 and DNMT3A 
rs7560488 and rs36012910 were the only associated with GC within published studies 
(Wu et al., 2014, 2012; Yang et al., 2012). The DNMT1 rs16999593 is characterized by 
a C>T variation, resulting in an Arg to His amino acid substitution at position 97 of the 
protein, leading to missense mutation that may affect the structure and function of 
DNMT1. Literature revealed that rs16999593 is significantly associated to some 
malignancies: Tao et. al showed that individuals with TC genotype presented a 4-fold 
increased risk for sporadic triple-negative breast carcinoma (Tao et al., 2015); Xiang et. 
al also revealed that rs16999593 can provide protective effect for ductal breast 
carcinoma (Xiang et al., 2010); and Yang et. al reported a 1.45-fold increased risk for 
TC+CC carriers and gastric cancer (Yang et al., 2012). Although these evidences, other 
studies do not show any association (Jiang et al., 2012; Ye et al., 2010). DNMT2  
rs11254413 is characterized by a G>A substitution leading to an amino acid change, His 
to Tyr at position 101 of the protein that may affect DNMT2 function (Yang et al., 2012). 
The A-allele was associated with protection risk for GC by Yang et al, nevertheless, there 
is no functional study that support the biological role of this SNP on DNMT2 function 
(Yang et al., 2012). The DNMT3A rs7560488 (variation T>C) is a tagSNP that represents 
SNPs of the DNMT3A1 promoter with high linkage disequilibrium and has been 
associated with higher risk for GC in Asiatic population (Wu et al., 2014). Authors 
suggested that T to C change influences the binding of transcriptional factors and 
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consequently expression levels of DNMT3a (Wu et al., 2014). The DNMT3A 
rs36012910, which is characterized by a A>G substitution located in the promoter region 
of DNMT3A and the substitution has been associated with DNMT3A activity (Wu et al., 
2012). Wu et al reveals that AG+GG genotypes were associated with a higher risk for 
GC (Wu et al., 2012). 
Regarding the data from the meta-analysis, we only were able to compare the 
information regarding 6 SNPs, which were described in more than one study. For DNMT1 
analysis, 3 SNPs were studied (rs16999593, rs8101866 and rs2228611) and only  
rs16999593 showed statistically significant data from the information of two different 
studies (Khatami et al., 2009; Yang et al., 2012) – figure 2. The results showed an 
increased risk for TC+CC genotypes of GC development. Nevertheless, the low number 
of studies and the lack of studies from populations apart from China make it necessary 
to perform more studies with different populations to confirm the association of 
rs16999593 with GC. Concerning DNMT3A, 2 SNPs were included in meta-analysis 
(rs1550117 and rs13420827) – figure 3. It was not found association of both SNPs with 
GC in the analysis. The heterogeneity analysis revealed differences only in rs1550117 
populations, because the ORs of Fan et al. were different comparing to the other studies 
(Fan et al., 2010). By removing Fan et al. of analysis, it became homogeneously but we 
did not find a significantly association with GC. The rs1550117 was the only SNP 
evaluated in three studies but analysis didn’t show an association with GC. The results 
in the studies were different, probably because of different genotype methods used in 
the three studies – table 1. 
Finally, we included one SNP in DNMT3B on the meta-analysis (rs1569686) – figure 4. 
We found no association of rs1569686 with GC. The analysis revealed heterogeneity 
because OR values of two studies were too different (0.43 in Hu et al. and 1.21 in Wang 
et al.) (Hu et al., 2010; Wang et al., 2015). 
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CONCLUSIONS 
We found 11 articles studying SNPs in DNMTs but the variety of SNPs and the reduced 
number of studies per each SNP made this analysis more complicated allowing us to 
draw only some remarks and not strong conclusions. The data from studies revealed 
that rs11254413, rs7560488, rs36012910 and, specially, rs16999593 seem to be good 
candidates to study the role of SNPs in DNMTs and GC development. Nevertheless, our 
meta-analysis revealed that only one SNP (rs16999593) in DNMT1 was statistically 
associated with GC development, especially TC+CC carriers. More studies with different 
populations are needed to prove if the SNPs selected in our analysis are associated with 
GC. Nevertheless, studies regarding biological importance of functional SNPs in DNMTs 
activity and expression are also need to fully understand the impact of SNPs in DNMTs 
on GC. 
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Table 1. Characteristics of all studies included in the analysis   
Reference 
Country 
(Ethnicity) 
Matching Criteria 
Cases Controls 
Gene SNPS (rs) 
Genotype 
method n Age n Age 
Wang et al.,2015 China (Asian) Age, gender and H. pylori 447 NA 961 NA DNMT3B 
rs6119954, rs1569686, 
rs4911107, rs4911259, rs8118663 
TaqMan assay 
Wu et al., 2014 China (Asian) Age and gender 405 NA 408 NA DNMT3A rs7560488 HRM 
Cao et al., 2013 China (Asian) Age, gender and H. pylori 447 61.6 961 50.6 DNMT3A rs1550117, rs13420827, TaqMan assay 
Wu et al., 2012 China (Asian) Age and gender 340 62.2* 251 62.7* DNMT3A rs36012910 PCR-RFLP 
Jiang et al., 2012 China (Asian) Age, gender and H. Pylori 447 61.6 961 50.6 DNMT1 
rs10420321, rs16999593, 
rs8101866, rs8111085, rs2288349 
TaqMan assay 
Yang et al., 2012 China (Asian) Age and gender 242 
54.9 ± 
12.5 
294 
58.4 ± 
16.4 
DNMT3A 
DNMT3B 
DNMT1 
DNMT2 
rs16999593, rs8101866, 
rs2228611, rs2114724, 
rs11254413, rs1550117, 
rs13420827, rs11887120, 
rs13428812, rs2424908 
MALDI-TOF 
Fan et al., 2010 China (Asian) Age and gender 208 65 346 71 DNMT3A rs1550117 PCR-RFLP 
Hu et al., 2010 China (Asian) Age and gender 259 64.0 262 65.1 DNMT3B rs1569686, rs2424913 PCR-RFLP 
Khatami et al., 
2009 
Iran (Turk and 
Fars) 
Age, gender and ethnicity 200 50±13 200 58±13 DNMT1 
rs721186, rs13784, rs2228611, 
rs11488 
PCR-RFLP 
Aung et al., 2005 Japan (Asian) NA 152 64,1* 247 43,9* DNMT3B rs2424913 PCR-RFLP 
Wang et al., 2005 China (Asian) Age and gender 212 60.4 294 59.1 DNMT3B rs2424913 PCR-RFLP 
NA, Not Available; * Median (range); H. Pylori - Helicobacter Pylori; DNMT1 - DNA (cytosine-5)-methyltransferase 1; DNMT2 - TRNA (cytosine38-C5)-methyltransferase; 
DNMT3A - DNA (cytosine-5)-methyltransferase 3 alpha; DNMT3B - DNA (cytosine-5-)-methyltransferase 3 beta; MALDI-TOF - Matrix-Assisted Laser Desorption/Ionization- Time 
of Flight; PCR-RFLP - Polymerase Chain Reaction-Restriction Fragment Length Polymorphism; HRM - High Resolution Melting. 
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Table 2.1 Genotyping results for DNMT1 of all studies included  
Gene SNP 
Genotype Distribution n (%) 
Analysis Model OR (95%CI) p value Reference 
Cases Controls 
D
N
M
T
1
 
rs10420321 
AA AG GG AA AG GG     
141 (31.5) 203 (51.5) 76 (17) 328 (34.1) 454 (47.2) 179 (18.6) CD 1.17 (0.88-1.55) (GG) 0.29 Jiang 2012 
rs16999593 
TT TC CC TT TC CC     
283 (63.3) 144 (32.2) 20 (4.5) 659 (68.6) 273 (28.4) 29 (3) CD 1.25(0.95-1.66) (TC) 0.18 Jiang 2012 
141 (58.3) 89 (36.8) 12 (5) 196 (66.7) 83 (28.2) 15 (5.1) 
CD 1.47 (1.01-2.14) (TC) 0.11 
Yang 2012 
Dominant 1.45 (1.00-2.11) (TC+CC) 0.05 
rs8101866 
CC CT TT CC CT TT     
238 (53.5) 177 (39.8) 30 (6.7) 489 (50.9) 402 (41.8) 70 (7.3) CD 0.81 (0.18-1.35) (CT) 0.11 Jiang 2012 
13 (5.4) 98 (40.1) 130 (53.9) 26 (8.8) 102 (34.7) 166 (56.5) 
CD 1.20 (0.83-1.74) (CT) 0.17 
Yang 2012 
Dominant 1.27 (0.89-1.82) (CT + CC) 0.19 
rs8111085 
TT TC CC TT TC CC     
143 (32) 214 (47.9) 90 (20.1) 330 (34.3) 447 (46.5) 184 (19.1) CD 1.18 (0.32-1.69) (CC) 0.38 Jiang 2012 
rs2288349 
GG GA AA GG GA AA     
249 (56.1) 161 (36.3) 34 (7.7) 515 (53.6) 372 (38.7) 74 (7.7) CD 0.81(0.50-1.33) (AA) 0.81 Jiang 2012 
rs2114724 
CC CT TT CC CT TT  
132 (54.5) 97 (40.1) 13 (5.4) 162 (56.2) 101 (35.1) 25 (8.7) 
CD 1,16 (0,81-1,68) (CT) 0,22 
Yang 2012 
Dominant 1.23 (0.86-1.76) (CT+TT) 0.27 
rs2228611 
GG GA AA GG GA AA     
132 (54.5) 97 (40.1) 13 (5.4) 160 (56.1) 99 (34.7) 26 (9.1) 
CD 1.18 (0.81-1.71) (GA) 0.14 
Yang 2012 
Dominant 1.26 (0.87-1.80) (GA+GG) 0.22 
34 (34) 50 (50) 16 (16) 32 (32) 62 (62) 18 (18) CD 1.13 (0.05-6.30) (GA) NA Khatami 2009 
rs721186 
CC CT TT CC CT TT     
99 (99) 1 (1) - 200 (100) - - NA NA NA Khatami 2009 
rs13784 
CC CT TT CC CT TT     
200 (100) - - 100 (100) - - NA NA NA Khatami 2009 
rs11488 
AA AT TT AA AT TT     
200 (100) - - 200 (100) - - NA NA NA Khatami 2009 
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Table 2.2 Genotyping results for DNMT2 of all studies included  
Gene SNP 
Genotype Distribution n (%) Analysis 
Model 
OR (95%CI) p value Reference 
Cases Controls 
DNMT2 rs11254413 
GG GA AA GG GA AA     
204 (84.3) 15 (6.2) 23 (9.5) 187 (63.8) 91 (31.1) 15 (5.1) 
CD 0.16 (0.09-0.28) (GA) <0.01 
Yang 2012 
Dominant 0.15 (0.08-0.27) (GA+AA) <0.01 
 
 
Table 2.3 Genotyping results for DNMT3A of all studies included  
Gene SNP 
Genotype Distribution n (%) Analysis 
Model 
OR (95%CI) p value Reference 
Cases Controls 
D
N
M
T
3
A
 
rs7560488 
TT TC CC TT TC CC     
279 (68.9) 111 (27.4) 15 (3.7) 326 (79.9) 75 (18.4) 7 (1.7) 
CD 
1.73(1.24-2.41) (TC); 
2.50(1.01-6.23) (CC) 
0.01; 
0.04 Wu 2014 
Dominant 1.65(1.19-2.29) (TC + CC) 0.002 
rs1550117 
GG GA AA GG GA AA     
289 (64.7) 142 (31.8) 16 (3.6) 640 (66.6) 288 (30) 33 (3.4) 
CD 1.10 (0.83-1.47) (AA) 0.51 
Cao 2013 
Dominant 1.06 (0.83-1.32) (GA+AA) 0.51 
157 (64.9) 74 (30.6) 11 (4.5) 191 (65) 93 (31.6) 10 (3.4) 
CD 1.34 (0.55-3.29) (AA) 0.74 
Yang 2012 
Dominant 0.92 (0.63-1.34) (GA+AA) 0.68 
102 (49) 75 (36.1) 31 (14.9) 218(63) 118 (34.1) 10 (2.9) CD 6.63 (3.13-14.03) (AA) 0.00 Fan 2010 
rs13420827 
CC CG GG CC CG GG     
295 (66) 133 (29.8) 19 (4.3) 618 (64.3) 304 (31.6) 39 (4.1) 
CD 1.06 (0.79-1.41) (GG) 0.71 
Cao 2013 
Dominant 1.05(0.83-1.33) (CG+GG) 0.64 
167 (69) 61 (25.2) 14 (5.8) 183 (62.7) 99 (33.9) 10 (3.4) 
CD 0.68 (0.46-1.01) (CG) 0.05 
Yang 2012 
Dominant 0.66 (0.45-0.97) (CG+GG) 0.03 
rs36012910 
AA AG GG AA AG GG     
288 (84.71) 51 (15) 1 (0.29) 234 (93.23) 17 (6.77) 0 
CD 2.44 (1.37-4.33) (AG) 0.002 
Wu 2012 
Dominant 2.36 (1.35-4.14) (AG+GG) 0.002 
rs11887120 
TT TC CC TT TC CC     
57 (23.6) 121 (50) 64 (26.4) 74 (25,3) 155 (53,1) 63 (21,6) CD 1.37 (0.88-2.13) (AA) 0.17 Wang 2015 
rs13428812 
AA AG GG AA AG GG     
137 (56.6) 84 (34.7) 21 (8.7) 160 (55.4) 106 (36.7) 23 (8) 
CD 1.11 (0.58-2.12) (GG) 0.84 
Yang 2012 
Dominant 0.91 (0.64-1.31) (AG+GG) 0.63 
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Table 2.4 Genotyping results for DNMT3A of all studies included  
Gene SNP 
Genotype Distribution n (%) Analysis 
Model 
OR (95%CI) p value Reference 
Cases Controls 
D
N
M
T
3
B
 
rs6119954 
GG GA AA GG GA AA     
200 (44.8) 199 (44.6) 4 (10.6) 433 (45.1) 445 (46.3) 83 (8.6) CD 1.37 (0.88-2.13) (AA) 0.17 Wang 2015 
rs1569686 
TT TG GG TT TG GG     
360 (80.5) 82 (18.3) 5 (1.1) 801 (83.4) 150 (15.6) 10 (1) CD 1.33 (0.41-4.31) (GG) 0.64 Wang 2015 
230 (88.8) 27 (10.43) 2 (0.77) 203 (77.48) 55 (20.99) 4 (1.53) Dominant 0.43 (0.26-0.72) (TG+GG) <0.01 Hu 2010 
rs4911107 
AA AG GG AA AG GG     
360 (80.5) 82 (18.3) 5 (1.1) 800 (83.2) 151 (15.7) 10 (1.1) CD 1.08 (0.13-8.86) (GG) 0.94 Wang 2015 
rs4911259 
GG GT TT GG GT TT     
359 (80.3) 83 (18.6) 5 (1.1) 799 (83.1) 152 (15.8) 10 (1.1) CD 1.09(0.13-8.88) (TT) 0.94 Wang 2015 
rs8118663 
AA AG GG AA AG GG     
126 (28.2) 233 (52.1) 88 (19.7) 314 (32.7) 473 (49.2) 174 (18.1) CD 1.32 (0.91-1.91) (GG) 0.15 Wang 2015 
rs2424908 
TT TC CC TT TC CC     
78 (32.2) 114 (47.1) 50 (20.7) 99 (33.7) 139 (47.3) 56 (19.1) 
CD 1.05 (0.64-1.71) (CC) 0.96 
Yang 2012 
Dominant 0.96 (0.68-1.36) (TC+CC) 0.82 
rs2424913 
CC CT TT CC CT TT     
257 (99.2) 2 (0.8) - 259 (98.8) 3 (1.2) - CD 1.49 (0.17-17.94) (CT) >0,05 Hu 2010 
152 (100) - - 247 (100) - - NA NA NA Aung 2005 
205 (96.7) 7 (3.3) - 279 (94.9) 15 (5.1) - Dominant 0.66 (0.26-1.67) (CT) 0,38 Wang 2005 
 
NA, Not Available; CD, Co-Dominant; NR, No Risk; DNMT1 – DNA (cytosine-5)-methyltransferase 1; DNMT2 – TRNA (cytosine38-C5)-methyltransferase; DNMT3a – DNA 
(cytosine-5)-methyltransferase 3 alpha; DNMT3b - DNA (cytosine-5-)-methyltransferase 3 beta; SNP – Single Nucleotide Polymorphism; Allele: A- Adenine, C- Cytosine, G- 
Guanine, T – Thymine; OR (95% CI) – Odds Ratio (95% Confidence Interval)
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Figure 1. Flow chart of studies identification, exclusion and inclusion. Adapted from: Moher D, 
Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for 
Systematic Reviews and Meta-analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097 
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Figure 2. Forest-plot for DNMT1 SNPs 
 
 
 
Figure 3. Forest-plot for DNMT3A SNPs  
 
 
 
Figure 4. Forest-plot for DNMT3B SNPs  
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Supplementary Table 1. Description of DNMTs SNPS included in the studies 
Gene 
(Chromosome) 
SNP Location 
Allele 
Change 
Amino Acid 
Change 
Function 
DNMT1 
(Chromosome 19) 
(19p13.2) 
rs11488 10133368 A/T NA 3' UTR 
rs13784 10133520 C/T NA 3' UTR 
rs2288349 10146569 G/A NA Intron 
rs2114724 10154572 C/T NA Intron 
rs721186 10154636 C/T Thr594 Synonymous codon 
rs2228611 10156401 G/A Pro463 Synonymous codon 
rs8111085 10162696 T/C Ile327Val Missense 
rs8101866 10164984 C/T NA Intron 
rs16999593 10180505 T/C His97Arg Missense 
rs10420321 10189741 A/G NA Intron 
DNMT2 
(Chromosome 10) 
(10p15.1) 
rs11254413 17162188 G/A His101Tyr Missense 
DNMT3A 
(Chromosome 2) 
(2p23) 
rs7560488 25345952 T/C NA NA 
rs1550117 25343038 G/A NA NearGene-5 
rs13420827 25231099 C/G NA NA 
rs36012910 25345310 A/G NA Promoter 
rs11887120 25262866 T/C NA Intron 
rs13428812 25269598 A/G NA Intron 
DNMT3B 
(Chromosome 20) 
(20q11.2) 
rs6119954 32776360 G/A NA Intron 
rs1569686 32779273 T/G NA Intron 
rs4911107 32787185 A/G NA Intron 
rs4911259 32788476 G/T NA Intron 
rs8118663 32811070 A/G NA NA 
rs2424908 32772577 T/C NA Intron 
rs2424913 32786453 C/T NA Intron 
NA, Not Available; DNMT1 – DNA (cytosine-5)-methyltransferase 1; DNMT2 – TRNA (cytosine38-C5)-
methyltransferase; DNMT3a – DNA (cytosine-5)-methyltransferase 3 alpha; DNMT3b - DNA (cytosine-5-)-
methyltransferase 3 beta; SNP – Single Nucleotide Polymorphism; Allele: A- Adenine, C- Cytosine, G- 
Guanine, T – Thymine; UTR – Untranslated Region 
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Supplementary Table 2. HWE in controls in all studies 
Gene SNP Reference HWE (p) 
DNMT1 
rs10420321 Jiang 2012 0.323 
rs16999593 
Jiang 2012 0.910 
Yang 2012 0.120 
rs8101866 
Jiang 2012 0.306 
Yang 2012 0.078 
rs8111085 Jiang 2012 0.139 
rs2288349 Jiang 2012 0.550 
rs721186 Khatami 2009 0.550 
rs13784 Khatami 2009 0.550 
rs2228611 
Khatami 2009 0.187 
Yang 2012 0.068 
rs11488 Khatami 2009 0.550 
rs2114724 Yang 2012 0.113 
DNMT2 rs11254413 Yang 2012 0.371 
DNMT3A 
rs7560488 Wu 2014 0.274 
rs1550117 
Cao 2013 0.932 
Yang 2012 0.747 
Fan 2010 0.206 
rs13420827 
Cao 2013 0.833 
Yang 2012 0.444 
rs36012910 Wu 2012 0.579 
rs11887120 Yang 2012 0.280 
rs13428812 Yang 2012 0.450 
DNMT3B 
rs6119954 Wang 2015 0.036 
rs1569686 
Wang 2015 0.321 
Hu 2010 0.901 
rs4911107 Wang 2015 0.341 
rs4911259 Wang 2015 0.362 
rs8118663 Wang 2015 0.859 
rs2424908 Yang 2012 0.563 
rs2424913 
Hu 2010 0.926 
Aung 2005 0.824 
Wang 2005 0.654 
DNMT1 – DNA (cytosine-5)-methyltransferase 1; DNMT2 – TRNA (cytosine38-C5)-methyltransferase; 
DNMT3A – DNA (cytosine-5)-methyltransferase 3 alpha; DNMT3B - DNA (cytosine-5-)-methyltransferase 3 
beta; HWE - Hardy–Weinberg equilibrium (http://www.had2know.com/academics/hardy-weinberg-
equilibrium-calculator-2-alleles.html) 
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ABSTRACT 
AIM: To investigate the relationship between the DNMT2 rs11254413 and DNMT3A1 
rs7560488 and the development of gastric lesions and gastric adenocarcinoma. 
METHODS: A case-control study was performed involving 380 individuals, 220 without 
evidence of neoplastic disease (control), 43 with gastric lesion and 117 patients with 
gastric adenocarcinomas. Genotyping was executed with TaqMan® SNP Genotyping 
Assay. 
RESULTS: The genotyping results for DNMT2 rs11254413 and DNMT3A1 rs7560488 
revealed no association with gastric lesion and gastric cancer. DNMT2 rs11254413 GG, 
GA and AA genotypes frequencies were 27.3%, 51.8% and 20.9%, respectively in 
controls; 25.6%, 48.8% and 25.6% in patients with gastric lesions; and 28.4%, 45.7% 
and 25.9% in patients with gastric adenocarcinoma. Regarding DNMT3A1 rs7560488 
analysis the frequencies of TT, TC and CC genotypes were 29.3%, 51.4% and 19.3%, 
respectively in controls, 35.7%, 47.6% and 16.7% in patients with gastric lesions and 
28.2%, 50.9% and 20.9% in patients with gastric adenocarcinoma. 
CONCLUSION: DNMT2 rs11254413 and DNMT3A1 rs7560488 may not be associated 
with the development of gastric lesions and gastric cancer. More studies, with different 
populations, are needed to confirm our findings.  
 
 
KEY WORDS 
DNA Methyltransferase; DNMT2; DNMT3A; Single Nucleotide polymorphism; Gastric 
Cancer  
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INTRODUTION 
Gastric cancer (GC) is one of the most common type of malignancies worldwide. It was 
the fifth common malignancy in 2012 worldwide (952,000 cases, 6.8% of the total) and 
the third leading cause of cancer deaths worldwide (723,000 deaths, 8.8% of the total) 
(1). According to Lauren’s classification, GC can be divided in two types: intestinal and 
diffuse type (2). The intestinal type is characterized by a stepwise carcinogenesis from 
normal mucosa through atrophic gastritis, atrophy, intestinal metaplasia and dysplasia 
to invasive adenocarcinoma (3,4). On the other hand, diffuse type is characterized by a 
less differentiated malignant neoplasia, without a well-marked multiple step process 
(3,4).   
The major risk factor for the development of GC is Helicobacter pylori infection 
(especially the intestinal type), nevertheless, GC can also be the result of specific genetic 
alterations. Another factor recently associated to CG has been epigenetic changes (5,6). 
Alterations in DNA methyltransferases (DNMTs), more precisely, DNMT1, DNMT2 and 
DNMT3A have been studied and have been suggested to have a role in carcinogenesis 
of GC (7,8,6,9). DNMTs are enzymes that catalyze the process of promoter methylation. 
There are three types of DNMTs: DNMT1, DNMT2 and DNMT3 (10). DNMT1 function is 
catalyze DNA post-replication methylation and maintain DNA methylation patterns during 
cell divisions (11,10,12). DNMT2 is the most conserved DNMT and their function is 
catalyze DNA and aspartic acid tRNA methylation (13). DNMT3 is divided in two types: 
DNMT3A and DNMT3B and they are responsible for de novo methylation during 
gametogenesis and embryogenesis (8). 
The most common form of genetic variants of the human genome are Single Nucleotide 
Polymorphisms (SNPs) (14) . Some SNPs have functional effects on the susceptibility to 
the development of human cancers by modifying the transcriptional expression 
(5,15,16). Several SNPs in DNMTs have been identified and some have been associated 
to GC risk (17,8,18). For example, SNP rs11254413 of DNMT2 leads to missense 
mutation of His to Tyr, and may also alter the function of the protein encoded by the 
DNMT2 gene. Yang 2012 demonstrated that GA genotype of rs11254413 has a 
potentially protective effect on GC risk (8). A study produced by Wu 2014 concluded that 
DNMT3A1 rs7560488 can be a promising biomarker to evaluate GC susceptibility (6). 
Other studies didn’t find an association between DNMTs SNPs and susceptibility for GC 
(17,18). 
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The aim of this study was to evaluate the association of DNMT2 and DNMT3A SNPs 
(rs11254413 and rs7560488, respectively) with the development of gastric lesions and 
gastric adenocarcinoma, in a population from the northern region of Portugal. 
 
METHODS 
Study Participants 
A retrospective hospital-based case-control study was developed with 43 patients with 
gastric lesion, 117 histologically confirmed GC patients and 220 cancer-free controls 
from the northern region of Portugal recruited at the Portuguese Institute of Oncology, 
Porto. Controls are healthy individuals without any clinical evidence of cancer selected 
from a database of blood donors. The characteristics of our population are presented in 
Table 1. An adjustment of gender and age it was taken into account to select controls. 
The study was submitted to the approval of Ethical Committee from host institution. 
Sample Collection and Processing 
In this study we used peripheral blood samples collected with standard venipuncture 
techniques in EDTA-containing tubes during routine clinical visits and stored in the 
institution archives. Total nucleic acids extraction was performed with QIAamp DNA 
Blood Mini Kit (QIAGEN, Venlo, Netherlands) according to manufacturer's instructions. 
DNA quality was assessed by measuring the absorbance at 260/280nm using an 
UV/Visible spectrophotometer and its purity assessed by the ratio of the values of 
absorbance at 260/280nm. The presence of amplifiable genomic DNA was tested with a 
PCR protocol for amplification of beta-globin gene (19). 
Genotyping of DNMTs SNPs 
The DNMTs SNPs, rs11254413 and rs7560488, were genotyped using the TaqMan® 
SNP Genotyping Assay C___2822597_10 and C__26104534_10, respectively (Applied 
Biosystems, Foster City CA, USA).  
Reactions were performed in a 5μL master containing 1x TaqMan Genotyping Master 
Mix (Applied Biosystems, Foster City CA, USA), 1x TaqMan® SNP Genotyping Assay 
(Applied Biosystems, Foster City CA, USA) and 10ng of DNA from each sample. 
Amplification was performed on the Applied Biosystems 7300 Real Time PCR System 
(Applied Biosystems, Foster City CA, USA) according to the manufacturer instructions.  
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Allelic discrimination was performed by measuring end-point fluorescence and analyzed 
by two authors. Negative controls were used using double distilled water and 10% of all 
samples were randomly selected and re-submitted to genotyping. 
Statistical analysis 
The Hardy–Weinberg equilibrium (HWE) was tested by calculated through the 
application of the online software (http://www.had2know.com/academics/hardy-
weinberg-equilibrium-calculator-2-alleles.html) to compare the observed versus the 
expected genotype frequencies. A p–value less than 0.05 of HWE was considered 
significant.  
Data analysis was performed using the computer software IBM SPSS Statistics for 
Windows, Version 22.0 (IBM Corp, Armonk NY, USA). Chi-square analysis was used to 
compare categorical variables, with a 5% level of significance. Multivariate logistic 
regression analysis was used to estimate odds ratio (OR) and its 95% confidence interval 
(CI) as a measure of the association between variant allele carriers and the risk for the 
development of gastric cancer. Potential confounding variables (age, gender) were 
addressed either by being included as covariates in the multivariate analysis or/and 
through data stratification. Homozygotes for the allele with the highest frequency was 
used as the reference group for each OR estimation. Variant allele carriers were defined 
as the heterozygous and minor allele homozygous genotype carriers pooled together 
(dominant model).  
 
RESULTS 
Allelic distribution of DNMT2 and DNMT3A SNPs 
The distribution of rs11254413 genotypes is shown in table 2. The frequency of the GG, 
GA and AA genotypes were 27.3%, 51.8% and 20.9%, respectively in controls; and 
25.6%, 48.8% and 25.6% in patients with gastric lesions and 28.4%, 45.7% and 25.9% 
in patients with gastric adenocarcinoma. The controls genotypic distribution was in HWE 
(p = 0.547). 
Regarding the distribution of rs7560488 genotypes, the frequencies of TT, TC and CC 
genotypes were 29.3%, 51.4% and 19.3%, respectively in controls, 35.7%, 47.6% and 
16.7% in patients with gastric lesions and 28.2%, 50.9% and 20.9% in patients with 
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gastric adenocarcinoma – table 3. The distribution of genetic variants in controls was in 
HWE (p = 0.431). 
Risk estimates for associated lesions and gastric adenocarcinoma 
Considering DNMT2 rs11254413 status, our results revealed no association with the 
development of gastric lesion and adenocarcinoma. We did not found statistically 
significant association with the development of gastric lesions and cancer (p = 0.793 and 
p = 0.488, respectively) – table 2.  
DNMT3A rs7560488 results revealed no statistically significant association with the 
development of gastric lesions or GC (p = 0.724 and p = 0.946, respectively) – table 3. 
 
DISCUSION 
DNA methylation was the first epigenetic mark linked directly with tumorigenesis. 
Aberrant CpG island methylation is associated to gene silencing and to cancer risk, 
including GC (16,20). DNMTs are responsible for DNA methylation and literature reveals 
that DNMTs are overexpressed in GC (21). Functional SNPs could affect DNMTs 
expression, therefore, it is important to study SNPs in DNMTs. 
DNMT2 rs11254413, leads to an amino acid change, His to Tyr, that may affect the  
function of DNMT2 and it has been described as associated with protection for GC (8). 
The other SNP analysed in this study, rs7560488, is a tagSNP representing different 
SNPs of DNMT3A promoter with high linkage disequilibrium (5). Nevertheless, this 
polymorphism seems to affect transcriptional activity of DNMT3A, resulting in altered 
expression of protein and TC+CC genotypes have been associated with increased risk 
for GC (5). Both these SNPs have only been studied in GC in one study each (5,8), and 
up to our knowledge, this is the first study within a southern European population from 
the northern region of Portugal reporting data regarding their role in GC development.  
Our results suggest that rs11254413 and rs7560488 have no relation with the 
development of gastric lesion and GC. These results are not in concordance with the 
results observed in the two studies regarding the two SNPs in study (5,8). The 
differences in the allele frequency, between regions, may explain the discordance of our 
results with the ones find in the literature, since the two studies were performed with 
Asiatic populations. We have compared the genetic distribution in our population with 
other populations as described in the HapMap Project. Table 4 describe the allele 
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frequency, in control population, of the two SNPs in 3 different regions, Asia, Europe and 
Africa. After analyse the data, it is possible to conclude that allele frequency of the two 
SNPs is similar comparing Europe and Africa, but major differences are found when 
comparing to Asiatic population: in rs11254413, the GA genotype is the most common 
genotype in Europe while GG genotype is the most common in Asia; and in rs7560488, 
the TC genotype is most common in Europe and the genotype with higher percentage in 
Asia is TT. Thus we can conclude that the genotypic distribution in our population is 
similar to those already described in Caucasian populations, which may represent a 
major genetic difference between these populations. 
 
CONCLUSION 
In conclusion, contribution of genetic polymorphisms to the risk of GC may be dependent 
on the population in study, as well on several environmental and dietary factors that 
influence that population. Our findings suggest these two SNPs (rs11254413 and 
rs7560488) do not seem to be associated with GC, nevertheless more studies, with 
larger Caucasian populations, are needed to clarify its role in GC susceptibility. 
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Table 1. Characteristics of the participants: age and gender  
 
Control 
n=220 
Gastric Atrophy 
n=43 
Gastric Adenocarcinoma 
n=117 
Age, years    
Mean ± SD 50.57 ± 6.67 59.56 ± 10.49 56.41 ± 11.24 
Median (Range) 51.00 (25 – 64) 59.00 (25 – 78) 59 (25 – 78) 
Gender, n    
Male 100 (45.5%) 19 (44.2%) 75 (64.1%) 
Female 120 (54.5%) 24 (55.8%) 42 (35.9%) 
SD- Standard Deviation 
 
Table 2. Genotype frequencies for DNMT2 SNP (rs11254413) 
DNMT2 rs11254413 GG GA AA p 
Normal 60 (27.3%) 114 (51.8%) 46 (20.9%) Ref. 
Lesion/Cancer 44 (27.7%) 74 (46.5%) 41 (25.8%) 0.477 
Lesion 11 (25.6%) 21 (48.8%) 11 (25.6%) 0.793 
Cancer 33 (28.4%) 53 (45.7%) 30 (25.9%) 0.488 
DNMT2 - TRNA (cytosine38-C5)-methyltransferase; Ref.- Reference 
 
Table 3. Genotype frequencies for DNMT3A SNP (rs7560488) 
DNMT3A rs7560488 TT TC CC p 
Normal 41 (29.3%) 76 (51.4%) 27 (19.3%) Ref. 
Lesion/Cancer 46 (30.3%) 76 (50.0%) 30 (19.7%) 0.970 
Lesion 15 (35.7%) 20 (47.6%) 7 (16.7%) 0.724 
Cancer 31 (28.2%) 56 (50.9%) 23 (20.9%) 0.946 
DNMT3A - DNA (cytosine-5)-methyltransferase 3A; Ref.- Reference 
 
Table 4. Allele frequency of rs11254413 and rs7560488 in different countries. Adapted from 
The International HapMap Project (22) 
Population Region 
rs11254413 rs7560488 
n GG GA AA n TT TC CC 
HapMap-CEU  Europe 224 25.88% 52.69% 21.43% 218 35.78% 53.21% 11.01% 
HapMap-HCB  Asia 86 51.16% 41.86% 6.98% 86 65.12% 30.23% 4.65% 
HapMap-JPT Asia 172 58.14% 37.21% 4.65% 172 67.44% 27.91% 4.65% 
HapMap-YRI  Africa 226 34.51% 46.90% 18.58% 220 33.64% 47.27% 19.09% 
CEU - Northern and Western European; HCB - Han Chinese in Beijing; JPT - Japanese in Tokyo; YRI - 
Yoruba in Ibadan, Nigeria 
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ABSTRACT 
AIM: To evaluate the relationship between SLC19A1 G80A and MTHFR C677T and the 
development of gastric lesions and gastric cancer. 
METHODS: We performed a case-control study including 427 Portuguese individuals: 
250 without evidence of neoplastic disease, 43 with gastric lesion and 137 patients with 
gastric adenocarcinomas). For genotyping proceeding was used a PCR-RFLP method. 
RESULTS: SLC19A1 G80A genotyping results revealed a protective effect for gastric 
lesion (OR = 0.373; 95%CI = 0.189-0.736; p = 0.006), but not for gastric cancer. 
Regarding MTHFR C677T results, we found an increased risk for GC development (OR 
= 2.046; CI 95% = 1.323-3.165; p = 0.001), but no association with gastric lesions.   
CONCLUSION: SLC19A1 G80A may have a protective role in gastric lesion 
development and MTHFR C677T may be associated with an increased risk for GC 
development, but more studies with Caucasian populations are needed to prove our 
findings.  
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Folates; SLC19A1; MTHFR; Single Nucleotide Polymorphism; Gastric Cancer 
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INTRODUTION 
Gastric cancer (GC) is one of the most common type of malignancies worldwide, 
representing the fifth common malignancy and the third leading cause of cancer deaths 
(1). GC can be divided in two types: intestinal type defined by a sequence of events from 
normal mucosa through atrophic gastritis, atrophy, intestinal metaplasia and dysplasia 
to invasive adenocarcinoma; and diffuse type characterized by a less differentiated 
malignant neoplasia, without a well-marked multiple step process (2,3,4). The 
development of GC is associated with several risk factors and the major one, especially 
for the development of the intestinal type, is Helicobacter pylori infection. GC can also 
be the result of specific genetic alterations, epigenetic alterations and other 
environmental factors, such as the low consumption of fruits and vegetables and, more 
specifically, folate deficiency. Literature reveals that low folate levels are correlated with 
development and invasiveness of GC (5). 
It is well known that gene expression can be influenced by a single nucleotide 
polymorphism (SNP). Polymorphisms in genes involved in folate metabolism, like 
SLC19A1 and MTHFR, may have functional consequences affecting levels of folate in 
plasma and therefore individual’s susceptibility to cancer. 
SLC19A1 80G>A is characterized by a substitution of a G by an A at position 80, leading 
to the change of arginine (Arg) into histidine (His) at codon 27 in the first transmembrane 
domain, a region implicated in carrier function (1,4). This polymorphism has been 
associated with differential activity of SLC19A1 and literature shows that it may modulate 
risk of gastric cancer (GC) (6,7). 
MTHFR C677T variant is characterized by a substitution of a C by a T at position 677, 
leading to a change of Alanine (Ala) into valine (Val) at codon 222, resulting in a 
thermolabile enzyme with reduced specific activity. Several studies have explored the 
potential association of this SNP with the susceptibility to GC (8,9). 
The aim of this case-study was to evaluate the association of SLC19A1 and MTHFR 
SNPs with the development of gastric lesions and gastric adenocarcinoma, in a 
population from the northern region of Portugal.  
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METHODS 
Study Participants 
A retrospective hospital-based case-control study was developed with 43 patients with 
gastric lesion, 137 histologically confirmed GC patients and 250 cancer-free controls 
from the northern region of Portugal recruited at the Portuguese Institute of Oncology, 
Porto. Controls are healthy individuals without any clinical evidence of cancer selected 
from a database of blood donors. The characteristics of our population are presented in 
Table 1. An adjustment for gender and age it was taken into account to select controls. 
The study was submitted to the approval of Ethical Committee from host institution. 
Sample Collection and Processing 
In this study, we used peripheral blood samples collected with standard venipuncture 
techniques in EDTA-containing tubes during routine clinical visits and stored in the 
institution archives. Total nucleic acids extraction was performed with QIAamp DNA 
Blood Mini Kit (QIAGEN, Venlo, Netherlands) according to manufacturer's instructions. 
DNA quality was assessed by measuring the absorbance at 260/280nm using an 
UV/Visible spectrophotometer and its purity assessed by the ratio of the values of 
absorbance at 260/280nm. The presence of amplifiable genomic DNA was tested with a 
PCR protocol for amplification of beta-globin gene (10). 
Polymorphisms genotyping 
The SLC19A1 G80A polymorphism (rs1051266) was genotyped by PCR-RFLP as 
previously described (11). PCR reaction was performed in a final volume of 50μl 
containing 1× DreamTaq® Green master mix (Thermo Fisher Scientific, MA USA), 0.3μM 
of each primer (forward 5´-AGTGTCACCTTCGTCCCCTC-3´ and reverse 5´-
CTCCCGCGTGAAGTTCTT-3´), 1 unit of DreamTaq® (Thermo Fisher Scientific, MA 
USA) and 50–100ng of genomic DNA. The PCR amplification consisted of initial 
denaturation at 95°C during 5min followed by 40 cycles with denaturation for 15s at 95°C, 
annealing/extension for 1min at 58°C and a final extension at 72°C for 7min. PCR 
product of 230bp was digested by CfoI (HhaI) (Thermo Fisher Scientific, MA USA) 
restriction endonuclease at 37°C for 1h. Individuals with the SLC19A1 80GG genotype 
presented two fragments (68 bp and 125 bp), individuals with the SLC19A1 80AA also 
presented two fragments (68 bp and 162 bp), whereas individuals with the SLC19A1 
80AG genotype presented three fragments (68 bp, 125 bp and 162 bp). 
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The MTHFR C677T polymorphism (rs1801133) was genotyped by PCR-RFLP as 
previously shown (12). PCR reaction was performed in a final volume of 50μl containing 
1× DreamTaq® Green master mix (Thermo Fisher Scientific, MA USA), 0.3μM of each 
primer (forward 5´-TGAAGGAGAAGGTGTCTGCGGGA-3´ and reverse 5´-
AGGACGGTGCGGTGAGAGTG-3´), 1 unit of DreamTaq® (Thermo Fisher Scientific, 
MA USA) and 50–100ng of genomic DNA. The PCR amplification consisted of initial 
denaturation at 94°C during 5min followed by 30 cycles with denaturation for 1min at 
94°C, annealing for 1min at 57°C, extension for 15s at 72°C, and a final extension at 
72°C for 10min. PCR product of 198bp was digested by HinfI (Thermo Fisher Scientific, 
MA USA) restriction endonuclease at 37°C for 1h. Individuals with the MTHFR 677CC 
genotype presented one fragment with 198bp, individuals with the MTHFR 677TT 
presented one fragment with 175bp, whereas individuals with the MTHFR 677CT 
genotype presented two fragments (198bp and 175bp). 
Genotypes were accessed by the interpretation of two authors. Negative controls were 
added to each PCR reaction using double distilled water to replace template DNA and 
10% of all samples were randomly selected and re-submitted to genotyping. 
Statistical analysis 
The Hardy–Weinberg equilibrium was calculated through online software 
(http://www.had2know.com/academics/hardy-weinberg-equilibrium-calculator-2-
alleles.html) to compare the observed versus the expected genotype frequencies and 
was considered significant a p–value less than 0.05. Data analysis was performed using 
the computer software IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp, 
Armonk NY, USA). Chi-square analysis was applied to compare categorical variables, 
using a 5% level of significance. Multivariate logistic regression analysis was used to 
estimate odds ratio (OR) and its 95% confidence interval (CI) as a measure of the 
association between variant allele carriers and the risk for the development of GC. 
Possible confounding variables, such as age and gender, were addressed either by 
being included as covariates in the multivariate analysis or/and through data 
stratification. Homozygotes for the allele with the highest frequency was used as the 
reference group for each OR estimation. Variant allele carriers were defined as the 
heterozygous and minor allele homozygous genotype carriers pooled together through 
a statistically dominant model. 
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RESULTS 
Allelic distribution of SLC19A1 G80A polymorphism 
The distribution of rs1051266 genotypes is shown in table 2. The frequency of the AA, 
AG, GG and Gcarrier genotypes were 21.2%, 50.2%, 28.6% and 78.8%, respectively in 
controls, 41.9%, 44.2%, 14.0% and 58.1% in patients with gastric lesions and 27.7%, 
48.2%, 24.1% and 72.3% in patients with gastric adenocarcinoma. The controls 
genotypic distribution was in HWE (p = 0.88). 
Allelic distribution of MTHFR C677T polymorphism  
Regarding the distribution of rs1801133 genotypes, the frequencies of CC, CT, TT and 
Tcarrier genotypes were 50.8%, 33.2%, 16.0% and 49.2%, respectively in controls, 
41.9%, 41.9%, 16.3% and 58.1% in patients with gastric lesions and 33.6%, 47.2%, 
17.2% and 66.4% in patients with gastric adenocarcinoma – table 3. The HWE was 
presented in controls genotypic distribution (p = 0.15). 
Risk estimates for associated lesions and gastric adenocarcinoma 
Table 2 describes the Odds Ratio (OR) for the development of gastric lesion and 
adenocarcinoma considering SLC19A1 G80A status. We found statistically significant 
risk for the development of gastric lesion (OR = 0.373; 95%CI = 0.189-0.736; p = 0.006). 
We observed a possible protective role for 80G carriers, and when the same analysis 
was adjusted for age and gender we also observed this protective role (OR = 0.347; 
95%CI = 0.158-0.762; p = 0.008). In contrast, we found no statistically significant risk for 
the development of GC (OR = 0.699; 95%CI = 0.430-1.136; p = 0.166). When the same 
analysis was adjusted for age and gender we also found the same no statistically 
significant results (OR = 0.692; 95%CI = 0.410-1.166; p = 0.167).   
Table 3 describes the OR for the development of gastric lesion and GC considering 
MTHFR C677T status. We found no statistically risk for the development of lesion (OR 
= 1.436; CI 95% = 0.745-2.771; p = 0.322). When the same analysis was adjusted for 
age and gender we also found the same no statistically significant results (OR = 1.155; 
CI 95% = 0.556-2.400; p = 0.700). In contrast, we found statistically significant risk for 
the development of GC (OR = 2.046; CI 95% = 1.323-3.165; p = 0.001). We observed a 
2-fold increased risk for the development of GC, and when the same analysis was 
adjusted for age and gender we also found a statistically significant risk for the 
development of GC (OR = 1.918; CI 95% = 1.209-3.044; p = 0.006).      
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DISCUSSION 
Literature revealed that lower serum folate levels are associated with development and 
invasiveness of gastric cancer (5). Folates are important for DNA methylation and 
nucleotide biosynthesis, and low levels of folate may result in DNA global 
hypomethylation, DNA damage, impaired DNA repair and altered oncogene and tumor 
suppressor gene expressions (5,13). Functional SNPs, in genes involved in folate 
metabolism, may affect folate levels, therefore, it is important to study SNPs in genes 
important for folate metabolism, such as, SLC19A1 and MTHFR. 
The SLC19A1 G80A polymorphism leads to an amino acid change of Arg into His at 
codon 27 in the first transmembrane domain, a region implicated in carrier function (1,4). 
In literature, we found only one study evaluating the association of SLC19A1 G80A 
polymorphism with GC development (7). Wang and colleagues reported a 1.43-fold 
increased risk for GC development (7).  
Literature reports other SNP in a protein involved in the folates metabolism that is often 
associated with other diseases (9,13–16). The MTHFR C677T, characterized by an 
amino acid change of Ala into Val at codon 222, results in a thermolabile enzyme with 
reduced specific activity (9). Indeed, this polymorphism has been shown to significantly 
increase susceptibility to gastric cancer (9,13–16).  
A study conducted by Chango et. al demonstrated that individuals with SLC19A1 80AA 
and MTHFR 677TT genotypes had significantly lower plasma folate levels and 
homocysteinemia (high level of homocysteine in blood) than individuals with wild-type 
SLC19A1 80GG and MTHFR 677CC genotypes (17). This evidence suggests a role for 
both SLC19A1 G80A and MTHFR C677T in the carcinogenesis of GC. 
SLC19A1 G80A and development of gastric lesion and GC 
SLC19A1 G allele seems to be extremely frequent (78.8%) in our population, which by 
comparison with data reported from other studies and from HapMap project is different 
among the different populations (Asia, Europe and Africa). The G allele is more frequent 
in Europe than in Asia and Africa. Moreover, our results for the genotype frequencies are 
in concordance with reported data in Caucasian populations – table 4. 
Our results suggest that SLC19A1 G80A is associated with a protective effect for gastric 
lesion (OR = 0.373; 95%CI = 0.189-0.736; p = 0.006), but not with GC. After an analysis 
adjusted for age and gender, the results remain statistically significant for gastric lesion 
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but not for GC – Table 1. Up to our knowledge, there is no study regarding the association 
of this SNP with gastric lesion. A meta-analysis performed by Huang et al. revealed a 
protective association with GC (GA+GG: OR = 0.89, 95%CI = 0.81-0.99, p = 0.030) (6). 
Our results also demonstrated the protective effect of G allele with GC but the results 
were not statically significant (OR = 0.699; 95%CI = 0.430-1.136; p = 0.166). 
MTHFR C677T and development of gastric lesion and GC 
Regarding MTHFR C677T allele frequency, our results shown that is no big difference 
between allele frequencies. The frequencies of this variant seem to diverge among 
different ethnic populations: C allele is more frequent in Europe and Africa, with the 
particularity that in Africa, the TT genotype is not present; in Asia the frequencies differ 
between countries, being the C allele more common in Japan and the T allele more 
frequent in China – Table 4. Furthermore, our results are not in concordance with the 
reported data in Caucasian populations, being more similar to those from Chinese allele 
frequencies. This results may be one factor to explain different risk susceptibilities of 
populations and may approximate us from those countries with higher incidences of GC 
when comparing to the European average rates (18). 
MTHFR C677T is associated with an increased risk for GC development (OR = 2.046; 
CI 95% = 1.323-3.165; p = 0.001), but was not associated with gastric lesions. The 
analysis adjusted for age and gender presented the same results – Table 2. Our results 
are in concordance with the results observed in the literature concerning the association 
of this SNP with GC (9,13–16). A meta-analysis presented by Yan et al. showed that, 
after stratified analyses according to ethnicity, MTHFR C677T may be a risk factor for 
gastric cancer among Asians and Caucasians (16). Regarding the association of MTHFR 
C677T with gastric lesion, to our knowledge, there is no study demonstrating this 
association, and despite we report a tendency for an increased risk for the development 
of gastric lesion (OR = 1.436; 95%CI = 0.745-2.771; p = 0.322) results were not statically 
significant.    
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CONCLUSIONS 
In conclusion, our findings suggest that SLC19A1 G80A may have a protective role in 
gastric lesion development and MTHFR C677T may be associated with an increased 
risk for GC development. Up to our knowledge, this is the first study within a southern 
European population, from the north region of Portugal evaluating the association of 
SLC19A1 G80A and MTHFR C677T polymorphisms. The contribution of genetic 
polymorphisms to the risk of GC may be dependent on the population in study, as well 
on several environmental and dietary factors that influence that population. More studies 
are needed, with Caucasian populations, to understand the relation of both SNPs with 
GC. 
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Table 1. Characteristics of the participants: age and gender 
 
Control 
n=250 
Gastric Atrophy 
n=43 
Gastric Adenocarcinoma 
n=117 
Age, years    
Mean ± SD 50.80 ± 6.86 59.56 ± 10.49 56.91 ± 11.14 
Median (Range) 51 (25 – 64) 59(25 – 78) 59 (25 – 78) 
Gender, n    
Male 124 (50.4%) 19 (44.2%) 84 (61.3%) 
Female 126 (49.6%) 24 (55.8%) 53 (38.7%) 
SD – Standard Deviation   
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Table 2. Genotype frequencies for SLC19A1 G80A polymorphism  
a adjusted for age and gender; OR- Odds Ratio; CI- Confidence Interval 
 
Table 3. Genotype frequencies for MTHFR C677T polymorphism 
MTHFR C677T CC CT TT Tcarrier OR CI (95%) p ORa CI (95%)a pa 
Normal 121 (50.8%) 79 (33.2%) 38 (16.0%) 117 (49.2%) 1.000 Reference 1.000 Reference 
Lesion/Cancer 64 (35.6%) 85 (47.2%) 31 (17.2%) 116 (64.4%) 1.874 1.260-2.788 0.002 1.693 1.108-2.587 0.015 
Lesion 18 (41.9%) 18 (41.9%) 7 (16.3%) 25 (58.1%) 1.436 0.745-2.771 0.322 1.155 0.556-2.400 0.700 
Cancer 46 (33.6%) 85 (47.2%) 31 (17.2%) 91 (66.4%) 2.046 1.323-3.165 0.001 1.918 1.209-3.044 0.006 
  a adjusted for age and gender; OR- Odds Ratio; CI- Confidence Interval 
SLC19A1 G80A GG GA AA Gcarrier OR CI (95%) p ORa CI (95%)a pa 
Normal 69 (28.6%) 121 (50.2%) 51 (21.2%) 190 (78.8%) 1.000 Reference 1.000 Reference 
Lesion/Cancer 39 (21.7%) 85 (47.2%) 56 (31.1%) 124 (68.9%) 0.594 0.382-0.924 0.024 0.551 0.340-0.894 0.016 
Lesion 6 (14.0%) 19 (44.2%) 18 (41.9%) 25 (58.1%) 0.373 0.189-0.736 0.006 0.347 0.158-0.762 0.008 
Cancer 33 (24.1%) 66 (48.2%) 38 (27.7%) 99 (72.3%) 0.699 0.430-1.136 0.166 0.692 0.410-1.166 0.167 
  
Table 4. Allele frequency of SLC19A1 G80A and MTHFR C677TT in different regions. Adapted from The International HapMap Project (1) 
Population Region n 
SLC19A1 G80A MTHFR C677TT 
GG AG AA Gcarrier CC CT TT Tcarrier 
HapMap-CEU  Europe 224 28.57% 55.36% 16.07% 56.25% 46.90% 44.25% 8.85% 30.97% 
HapMap-HCB  Asia 86 25.58% 46.51% 27.91% 48.84% 27.91% 41.86% 30.23% 51.16% 
HapMap-JPT Asia 172 19.77% 48.84% 31.39% 44.19% 39.53% 48.84% 11.63% 36.05% 
HapMap-YRI  Africa 226 13.27% 35.40% 51.33% 30.97% 81.42% 18.58% - 9.29% 
CEU - Northern and Western European; HCB - Han Chinese in Beijing; JPT - Japanese in Tokyo; YRI - Yoruba in Ibadan, Nigeria 
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FINAL DISCUSSION AND CONCLUSIONS 
Gastric Cancer is a major cause of cancer-related deaths worldwide (4). In Portugal, GC 
is the fifth cause of death by cancer (4). The majority of patients with GC are diagnosed 
in advanced stages, leading to a poor prognosis (37).Therefore, it is important to 
implement preventive strategies, such as population screening and genetic susceptibility 
tests, to allow the detection of GC at early stages.  
In this thesis we have been focused on genetic risk markers of GC susceptibility 
associated with two of the risk factors for GC development: altered DNA methylation and 
low folate intake. Literature revealed that genes involved in carcinogenesis accumulate 
aberrant methylation patterns (26) and additionally, studies have also found an 
association between low folate levels and development and invasiveness of GC (22). 
Genetic alterations, such as SNPs, have been described as important predictors of 
cancer development and a great number of them have the ability to modulate gene 
expression. Therefore, the study of SNPs in genes responsible for DNA methylation and 
folate metabolism may contribute for a better knowledge of genetic influence on 
individual’s susceptibility to GC development. 
DNA Methylation 
We started by performing a systematic review and meta-analysis to understand what has 
been described in literature regarding the role of SNPs in DNMTs and GC development, 
in order to attempt to clarify which SNPs could be important to study. From a total of 24 
SNPs reported, we found that only 4 SNPs seem to have some association with GC. The 
DNMT2 rs11254413, DNMT3A rs7560488 and rs36012910 and, specially, DNMT1 
rs16999593 seemed to be good candidates to study the role of SNPs in DNMTs with  
GC – figure 5. 
The DNMT1 rs16999593 C>T variation results in a missense mutation caused by a His 
to Arg amino acid substitution at position 97 of DNMT1 promoter (33). A study performed 
by Yang and colleagues revealed that DNMT1 rs16999593 C allele was associated with 
an increased risk of GC (OR = 1.45; 95%CI = 1.00-2.11; p = 0.05) (38). Moreover, Jiang 
et al. results showed an association of DNMT1 rs16999593 in GC but the results were 
not statistically significant (33). Nevertheless, the influence of this SNP on DNMT1 
function is still unknown. We hypothesized that DNMT1 rs16999593 variation may have 
an effect on structure and function of the protein. 
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Figure 5. SNPs in DNMTs candidates for association with GC.  
 
DNMT1 is responsible for the methylation of newly biosynthesized DNA strands after 
replication (39). Literature showed that DNMT1 expression levels are significantly higher 
in GC patients (40–42). DNMT1 increased expression levels are associated with 
hypermethylation of CGI and, therefore, tumor suppressor genes silencing (43). Genetic 
variants in DNMT1 promoter, such as rs16999593, may have an impact in GC 
carcinogenesis and contribute to genetic susceptibility to GC. 
The literature systematic review also revealed that DNMT2 rs11254413 A allele was 
associated to a protective effect against GC (OR = 0.15; 95%CI = 0.08-0.27); p < 0.01) 
(38). DNMT2 rs11254413 is characterized by a G>A allele change leading to a His to 
Tyr missense mutation in position 101. DNMT2 is responsible for aspartic acid tRNA and 
residual DNA (cytosine-C5) methylation, nevertheless, there are needed future studies 
to understand the impact of DNMT2 in cellular pathways (44). The results presented by 
Yang et al. suggest a potentially protective effect of DNMT2 rs11254413 on GC risk, but 
more studies are needed to prove this association, since this was the only study 
analyzing an association of DNMT2 rs11254413 with GC. 
Finally, regarding DNMT3A literature analysis, we found two SNPs with a statistically 
significant association with GC: rs7560488 and rs36012910. The C allele of DNMT3A1 
rs7560488 was associated with an increased risk for GC (OR = 1.65; 95%CI = 1.19-2.29; 
p = 0.002) (45). DNMT3A rs7560488 T>C variation is a putative functional tagSNP, which 
means that represents all SNPs from DNMT3A promoter with high linkage disequilibrium 
(35,45). Wu and colleagues also performed assays to understand the impact of this 
RISK Protection
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tagSNP in DNMT3A expression. The results revealed that the expression levels of 
DNMT3A1 mRNA was lower in individuals with C allele (p<0.05) (45). DNMT3A 
rs7560488 T>C variation have an effect on the binding of transcriptional factors, which 
results in an altered transcriptional activity of DNMT3A1 gene (45). Therefore, these 
findings suggest that DNMT3A rs7560488 may regulate DNMT3A expression and 
contribute for GC susceptibility. Another SNP in DNMT3A statistically significant 
associated with GC was rs36012910. Individuals with the G allele of DNMT3A 
rs36012910 presented an increased risk for GC when compared to controls (OR = 2.36; 
95%CI = 1.35-4.14; p = 0.002) (46). This SNP is localized on the transcription start site 
in the promoter region of DNMT3A and is characterized by an A to G allele change (46). 
By bioinformatics analyses, Wu and his colleagues hypothesized that DNMT3A is a 
functional SNP with impact on the DNMT3A promoter activity, and, therefore, may be 
associated with GC (46). Future studies are needed to confirm the biological impact of 
DNMT3A rs rs36012910 and the association with GC.    
Furthermore, we have attempted to summarize the data in literature with a meta-
analysis, and we found that from the 24 SNPs, only 6 SNPs were evaluated in more than 
one study, which clearly reduces the data available for the meta-analysis. Our results 
revealed that only rs16999593 was associated with GC, showing statistically significant 
increased risk (OR = 1.31; 95% CI = 1.08-1.60; p=0.006) for TC+CC genotypes. Only 
two studies evaluate this association, both in Asiatic populations. As described before, 
more studies are needed to understand the functional impact of this SNP. Besides, this 
results suggest that Chinese individuals carrying DNMT1 rs16999593 C allele have an 
increased risk for GC, and more studies with different populations are needed to confirm 
the association of DNMT1 rs16999593 with GC. 
After the literature systematic review and meta-analysis, we decided to evaluate 3 
different SNPs in DNMTs: DNMT1 rs16999593, DNMT2 rs11254413 and DNMT3A 
rs7560488. We decided to study one SNP for each DNMT, according to systematic 
review and meta-analysis results. All chosen SNPs presented promising associations 
with GC and we aimed to characterize the genotyping distribution for the three SNPs in 
our population. Unfortunately, we only were capable to studied DNMT2 rs11254413 and 
DNMT3A rs7560488 because of technical issues with the assay for the other SNP that 
did not allowed us to do a correct interpretation of genotypes and therefore we have 
decided to exclude it from the study. Our results revealed no association of both SNPs 
with gastric lesions and cancer development. Nevertheless, the findings of our study are 
not in agreement with the literature available. Only two studies evaluate the association 
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of DNMT2 rs11254413 and DNMT3A rs7560488 with GC (38,45). The results, also 
explored before, showed that DNMT2 rs11254413 A allele may have a protective effect 
for GC and DNMT3A rs7560488 C allele may be associated with an increased risk for 
GC. The majority of studies regarding SNPs in DNMTs and association with GC were 
performed with Asian populations and there are no studies with Caucasian populations. 
We found no association with gastric lesion and GC in our population, nevertheless, this 
was the first study evaluating the association of DNMT2 rs11254413 and DNMT3A 
rs7560488 in a European population and more studies are needed to confirm our 
findings. 
Folate Metabolism 
Finally, we also performed a study to understand the association of SNPs in genes 
essential for folate metabolism with gastric lesions and GC. We selected two important 
genes that have been studied: SLC19A1 and MTHFR (47,48). Our study demonstrated 
an association between SLC19A1 G80A and gastric lesions development and MTHFR 
C677T and GC development.  
SLC19A1 G80 is associated with a protective effect for gastric lesions (OR = 0.373; 
95%CI = 0.189-0.736; p = 0.006), but not with GC. According to literature, there is only 
one study evaluating the association of SLC19A1 G80A with GC (49). The results 
showed a protective effect of G allele for GC, which is in line with our results although 
we do not find a statistically significant association. This is the first study to evaluate the 
association of this SNP with gastric lesions.    
On the other hand, MTHFR C677T is associated with an increased risk for GC 
development (OR = 2.046; 95%CI = 1.323-3.165; p = 0.001 for T allele), but was not 
associated with gastric lesions. Up to our knowledge, there is no studies to demonstrate 
the association between MTHFR C677T and gastric lesions, still, several studies have 
been performed concerning the association of this SNP with GC (50–54). All studies 
suggest that T allele is associated with an increased risk for GC development. Therefore, 
MTHFR C677T seem like a good biomarker for GC susceptibility.      
Folates are B vitamins naturally present in many foods, important for DNA regulation, 
including DNA methylation (51). In folate metabolism, SLC19A1 or RFC1 is responsible 
for transport of active form of folate 5-MTHF and MTHFR has the capacity to convert 
folates in to the reduced and active form 5-MTHF. Without 5-MTHF, there is no 
conversion of homocysteine in methionine and, therefore, no formation of SAM, a methyl 
group donor crucial for DNA methylation catalysed by DNMTs – figure 6. 
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Figure 6. Homocysteine cycle. The 5-MTHF is a methyl donor for the conversion of homocysteine 
into methionine and SAM is a methyl donor for DNA methylation. (5-MTHF – 5-Methylene 
tetrahydrofolate; SAM - S-Adenosyl methionine) 
Literature showed that individuals with SLC19A1 80AA and MTHFR 677TT genotypes 
had significantly lower plasma folate levels and homocysteinemia (high level of 
homocysteine in blood), comparing to individuals with wild-type SLC19A1 GG80 and 
MTHFR CC677 genotypes (17). The results of Chango and his colleagues suggests that 
SLC19A1 G80A and MTHFR C677T influence protein function and, therefore, 
carcinogenesis of GC (17). 
Conclusions 
In conclusion, our study demonstrated that DNMT2 rs11254413 and DNMT3A 
rs7560488 are not associated with gastric lesions and GC in our population, but, 
otherwise, SLC19A1 G80A and MTHFR C677T seem to have an impact on susceptibility 
for gastric lesions and GC, respectively. These results suggest that SLC19A1 G80A and 
MTHFR C677T may have a role in gastric carcinogenesis, though this observation needs 
to be complemented with further studies, including larger studies with different ethnic 
populations and functional studies regarding the effect of both SNPs in gene expression.
Homocysteine
Methionine
SAM
DNA Methylation 
5-MTFH 
  
    
  
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6 
  
  
CHAPTER 6 
Polymorphisms in DNA regulation-associated genes and GC development |62 
 
REFERENCES 
 
1.  Kanwal R, Gupta K, Gupta S. Cancer epigenetics: an introduction. Methods Mol 
Biol [Internet]. 2015 [cited 2016 Jul 16];1238:3–25. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/25421652 
2.  Stewart BW, Wild C, International Agency for Research on Cancer., World Health 
Organization. World cancer report 2014. International Agency for Research on 
Cancer; 2014. 916 p.  
3.  Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, 
Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and 
Mortality Worldwide. IARC CancerBase No 11 [Internet] [Internet]. 2013;Lyon, 
Fran. Available from: http://globocan.iarc.fr 
4.  Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer 
incidence and mortality worldwide: sources, methods and major patterns in 
GLOBOCAN 2012. Int J cancer [Internet]. 2015 Mar 1 [cited 2016 Jul 
16];136(5):E359-86. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/25220842 
5.  Lauren P. The two histological main types of gastric carcinoma: diffuse and so-
called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta 
Pathol Microbiol Scand [Internet]. 1965 [cited 2016 Jul 26];64:31–49. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/14320675 
6.  Carl-Mcgrath S, Ebert M, Röcken C. Gastric adenocarcinoma: epidemiology, 
pathology and pathogenesis. Cancer Ther Vol Cancer Ther. 2007;5(5):877–94.  
7.  Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: 
Classification, histology and application of molecular pathology. J Gastrointest 
Oncol [Internet]. 2012;3(3):251–61. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3418539&tool=pmcen
trez&rendertype=abstract 
8.  McLean MH, El-Omar EM. Genetics of gastric cancer. Nat Rev Gastroenterol 
Hepatol [Internet]. 2014 Nov [cited 2016 Aug 17];11(11):664–74. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/25134511 
9.  Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric 
cancer: descriptive epidemiology, risk factors, screening, and prevention. Am 
Assoc Cancer Res [Internet]. NIH Public Access; 2014 May [cited 2016 Jul 
26];23(5):700–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24618998 
10.  Yoon H, Kim N. Diagnosis and management of high risk group for gastric cancer. 
Gut Liver [Internet]. Editorial Office of Gut and Liver; 2015 Jan [cited 2016 Jul 
26];9(1):5–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25547086 
11.  D’Elia L, Rossi G, Ippolito R, Cappuccio FP, Strazzullo P. Habitual salt intake and 
risk of gastric cancer: a meta-analysis of prospective studies. Clin Nutr [Internet]. 
Elsevier; 2012 Aug [cited 2016 Jul 30];31(4):489–98. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/22296873 
12.  Wiseman M. The second World Cancer Research Fund/American Institute for 
Cancer Research expert report. Food, nutrition, physical activity, and the 
prevention of cancer: a global perspective. Proc Nutr Soc [Internet]. 2008 Aug 
[cited 2016 Jul 30];67(3):253–6. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/18452640 
13.  Nagini S. Carcinoma of the stomach: A review of epidemiology, pathogenesis, 
molecular genetics and chemoprevention. World J Gastrointest Oncol [Internet]. 
2012 Jul 15 [cited 2016 Jul 30];4(7):156–69. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/22844547 
14.  Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA. Environmental and 
chemical carcinogenesis. Semin Cancer Biol. 2004;14(6):473–86.  
15.  Sousa H, Pinto-Correia A-LL, Medeiros R, Dinis-Ribeiro M. Epstein-Barr virus is 
CHAPTER 6 
Polymorphisms in DNA regulation-associated genes and GC development |63 
 
associated with gastric carcinoma: The question is what is the significance? World 
J Gastroenterol [Internet]. 2008 Jul 21 [cited 2016 Jul 30];14(27):4347–51. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/18666324 
16.  Fukayama M. Epstein-Barr virus and gastric carcinoma. Pathol Int [Internet]. 2010 
May [cited 2016 Jul 30];60(5):337–50. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/20518883 
17.  Fu D-G. Epigenetic alterations in gastric cancer (Review). Mol Med Rep [Internet]. 
Spandidos Publications; 2015 Sep [cited 2016 Jul 30];12(3):3223–30. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/25997695 
18.  Levine AJ, Lee W, Figueiredo JC, Conti D V., Vandenberg DJ, Davis BD, et al. 
Variation in folate pathway genes and distal colorectal adenoma risk: A 
sigmoidoscopy-based case-control study. Cancer Causes Control. 
2011;22(4):541–52.  
19.  Zacho J, Yazdanyar S, Bojesen SE, Tybjærg-Hansen A, Nordestgaard BG. 
Hyperhomocysteinemia, methylenetetrahydrofolate reductase c.677C>T 
polymorphism and risk of cancer: Cross-sectional and prospective studies and 
meta-analyses of 75,000 cases and 93,000 controls. Int J Cancer. 
2011;128(3):644–52.  
20.  Mayne ST, Risch HA, Dubrow R, Chow WH, Gammon MD, Vaughan TL, et al. 
Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer 
Epidemiol Biomarkers Prev [Internet]. 2001;10(10):1055–62. Available from: 
http://libaccess.mcmaster.ca/login?url=http://ovidsp.ovid.com/ovidweb.cgi?T=JS
&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11588131\nhttp://sfx.scholar
sportal.info/mcmaster?sid=OVID:medline&id=pmid:11588131&id=doi:&issn=105
5-9965&isbn=&volume=10&issue=10&spage=1 
21.  Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, 
pathways and beyond. Nat Rev Cancer [Internet]. 2003 Dec [cited 2016 Sep 
7];3(12):912–20. Available from: 
http://www.nature.com/doifinder/10.1038/nrc1233 
22.  Lee TY, Chiang EP, Shih YT, Lane HY, Lin JT, Wu CY. Lower serum folate is 
associated with development and invasiveness of gastric cancer. World J 
Gastroenterol. 2014;20(32):11313–20.  
23.  Liang S, Zhou Y, Wang H, Qian Y, Ma D, Tian W, et al. The effect of multiple 
single nucleotide polymorphisms in the folic acid pathway genes on homocysteine 
metabolism. Biomed Res Int. Hindawi Publishing Corporation; 2014;2014.  
24.  Zhang D, Wen X, Wu W, Guo Y, Cui W. Elevated homocysteine level and folate 
deficiency associated with increased overall risk of carcinogenesis: Meta-analysis 
of 83 case-control studies involving 35,758 individuals. PLoS One. 2015;10(5):1–
16.  
25.  Gotze T, Rocken C, Rohl FW, Wex T, Hoffmann J, Westphal S, et al. Gene 
polymorphisms of folate metabolizing enzymes and the risk of gastric cancer. 
Cancer Lett. 2007;251(2):228–36.  
26.  Qu Y, Dang S, Hou P. Gene methylation in gastric cancer. Clin Chim Acta 
[Internet]. 2013 Sep 23 [cited 2016 Jan 12];424:53–65. Available from: 
http://www.sciencedirect.com/science/article/pii/S0009898113001964 
27.  Hitchler MJ, Domann FE. An epigenetic perspective on the free radical theory of 
development. Free Radic Biol Med [Internet]. NIH Public Access; 2007 Oct 1 [cited 
2016 Jul 29];43(7):1023–36. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/17761298 
28.  Tie J, Zhang X, Fan D. Epigenetic roles in the malignant transformation of gastric 
mucosal cells. Cell Mol Life Sci [Internet]. Springer International Publishing; 2016 
Jul 27 [cited 2016 Aug 16];1–12. Available from: 
http://link.springer.com/10.1007/s00018-016-2308-9 
29.  Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 
[Internet]. Elsevier; 2011 Mar 4 [cited 2016 Jul 26];144(5):646–74. Available from: 
CHAPTER 6 
Polymorphisms in DNA regulation-associated genes and GC development |64 
 
http://www.ncbi.nlm.nih.gov/pubmed/21376230 
30.  Calcagno DQ, de Arruda Cardoso Smith M, Burbano RR. Cancer type-specific 
epigenetic changes: gastric cancer. Methods Mol Biol [Internet]. 2015 [cited 2016 
Jul 16];1238:79–101. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/25421656 
31.  Brookes AJ. The essence of SNPs. Gene [Internet]. 1999 Jul [cited 2016 Aug 
17];234(2):177–86. Available from: 
http://linkinghub.elsevier.com/retrieve/pii/S037811199900219X 
32.  Haiman CA, Stram DO. Exploring genetic susceptibility to cancer in diverse 
populations. Curr Opin Genet Dev [Internet]. NIH Public Access; 2010 Jun [cited 
2016 Sep 8];20(3):330–5. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/20359883 
33.  Jiang J, Jia Z, Cao D, Jin M-S, Kong F, Suo J, et al. Polymorphisms of the DNA 
methyltransferase 1 associated with reduced risks of Helicobacter pylori infection 
and increased risks of gastric atrophy. PLoS One [Internet]. United States; 2012 
Jan [cited 2016 Apr 19];7(9):e46058. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3457938&tool=pmcen
trez&rendertype=abstract 
34.  Saradalekshmi KR, Neetha NV, Sathyan S, Nair I V, Nair CM, Banerjee M. DNA 
methyl transferase (DNMT) gene polymorphisms could be a primary event in 
epigenetic susceptibility to schizophrenia. PLoS One [Internet]. 2014 Jan [cited 
2016 Apr 19];9(5):e98182. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4032286&tool=pmcen
trez&rendertype=abstract 
35.  Easton DF, Eeles RA. Genome-wide association studies in cancer. Hum Mol 
Genet [Internet]. 2008 Oct 15 [cited 2016 Sep 8];17(R2):R109-15. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/18852198 
36.  Wooster R, Bachman KE. Catalogue, cause, complexity and cure; the many uses 
of cancer genome sequence. Curr Opin Genet Dev [Internet]. 2010 Jun [cited 
2016 Sep 8];20(3):336–41. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/20382522 
37.  Waddell T, Verheij M, Allum W, Cunningham D, Cervantes  a., Arnold D. Gastric 
cancer+: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, 
treatment and follow-up. Ann Oncol. 2013;24(SUPPL.6).  
38.  Yang X-X, He X-Q, Li F-X, Wu Y-S, Gao Y, Li M. Risk-association of DNA 
methyltransferases polymorphisms with gastric cancer in the southern chinese 
population. Int J Mol Sci. Switzerland; 2012;13(7):8364–78.  
39.  Hermann A, Goyal R, Jeltsch A. The Dnmt1 DNA-(cytosine-C5)-methyltransferase 
methylates DNA processively with high preference for hemimethylated target 
sites. J Biol Chem. 2004;279(46):48350–9.  
40.  Kanai Y, Ushijima S, Kondo Y, Nakanishi Y, Hirohashi S. DNA methyltransferase 
expression and DNA methylation of CPG islands and peri-centromeric satellite 
regions in human colorectal and stomach cancers. Int J Cancer [Internet]. 2001 
Jan 15 [cited 2016 Feb 25];91(2):205–12. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/11146446 
41.  Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H, Hirohashi S. Expression of mRNA 
for DNA methyltransferases and methyl-CpG-binding proteins and DNA 
methylation status on CpG islands and pericentromeric satellite regions during 
human hepatocarcinogenesis. Hepatology [Internet]. 2001 Mar [cited 2016 Feb 
25];33(3):561–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11230735 
42.  Etoh T, Kanai Y, Ushijima S, Nakagawa T, Nakanishi Y, Sasako M, et al. 
Increased DNA methyltransferase 1 (DNMT1) protein expression correlates 
significantly with poorer tumor differentiation and frequent DNA hypermethylation 
of multiple CpG islands in gastric cancers. Am J Pathol. 2004;164(2):689–99.  
43.  Guo M, Yan W. Epigenetics of gastric cancer. Methods Mol Biol [Internet]. 2015 
CHAPTER 6 
Polymorphisms in DNA regulation-associated genes and GC development |65 
 
[cited 2016 Jul 16];1238:783–99. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/25421692 
44.  Goll MG, Kirpekar F, Maggert K a, Yoder J a, Hsieh C-L, Zhang X, et al. 
Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science 
(80- ) [Internet]. 2006;311(5759):395–8. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/16424344 
45.  Wu H, Zhang K, Gong P, Qiao F, Wang L, Cui H, et al. A novel functional TagSNP 
Rs7560488 in the DNMT3A1 promoter is associated with susceptibility to gastric 
cancer by modulating promoter activity. PLoS One. United States; 
2014;9(3):e92911.  
46.  Wu Q, Lu S, Wang L, Hu J, Qiao F, Qiu X, et al. DNMT3A rs36012910 A>G 
polymorphism and gastric cancer susceptibility in a Chinese population. Mol Biol 
Rep. Netherlands; 2012 Dec;39(12):10949–55.  
47.  Ganapathy V, Smith SB, Prasad PD. SLC19: The folate/thiamine transporter 
family. Pflugers Arch Eur J Physiol. 2004;447(5):641–6.  
48.  DeRoo LA, Bolick SCE, Xu Z, Umbach DM, Shore D, Weinberg CR, et al. Global 
DNA methylation and one-carbon metabolism gene polymorphisms and the risk 
of breast cancer in the Sister Study. Carcinogenesis. 2014;35(2):333–8.  
49.  Wang L, Chen W, Wang J, Tan Y, Zhou Y, Ding W, et al. Reduced folate carrier 
gene G80A polymorphism is associated with an increased risk of 
gastroesophageal cancers in a chinese population. Eur J Cancer. 
2006;42(18):3206–11.  
50.  Xiong H-L, Liu X-Q, Sun A-H, He Y, Li J, Xia Y. Aberrant DNA methylation of P16, 
MGMT, hMLH1 and hMSH2 genes in combination with  the MTHFR C677T 
genetic polymorphism in gastric cancer. Asian Pac J Cancer Prev. Thailand; 
2013;14(5):3139–42.  
51.  Gao S, Ding L-H, Wang J-W, Li C-B, Wang Z-Y. Diet folate, DNA methylation and 
polymorphisms in methylenetetrahydrofolate reductase in association with the 
susceptibility to gastric cancer. Asian Pac J Cancer Prev. Thailand; 
2013;14(1):299–302.  
52.  Xia L-Z, Liu Y, Xu X-Z, Jiang P-C, Ma G, Bu X-F, et al. Methylenetetrahydrofolate 
reductase C677T and A1298C polymorphisms and gastric cancer susceptibility. 
World J Gastroenterol [Internet]. 2014 Aug 28 [cited 2016 Sep 9];20(32):11429–
38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25170232 
53.  Lv L, Wang P, Sun B, Chen G. The polymorphism of methylenetetrahydrofolate 
reductase C677T but not A1298C contributes to gastric cancer. Tumour Biol 
[Internet]. 2014 Jan [cited 2016 Sep 9];35(1):227–37. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/23897558 
54.  Yan S, Xu D, Wang P, Wang P, Liu C, Hua C, et al. MTHFR C677T polymorphism 
contributes to the risk for gastric cancer. Tumour Biol [Internet]. 2014 Mar [cited 
2016 Sep 9];35(3):2123–32. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/24122207 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
ATTACHMENTS 
